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ABSTRACT
1
 
Endothelial specific microRNA-126 (miR-126) is required for angiogenesis during 
development and repair of injured arterial vasculature in adult. Endothelial cells are a diverse 
group of cells with distinct molecular and functional features. The role of miR-126 in the 
microvascular beds, specifically in the lung microvasculature that are essential for alveolar gas 
exchange and lung repair and regeneration, remains largely undefined. Previous work has 
reported an anti-angiogenic function of miR-126 in highly proliferative cell types such as late 
endothelial progenitor cells and in diseases featuring neovascularization such as diabetic 
retinopathy and various cancers. The mechanism underlying the discrepancy of miR-126 
functions is unknown. In this dissertation, by engaging a variety of approaches we aimed to 
determine the functional impact of miR-126 in primary human lung microvascular endothelial 
cells (HLMVEC) and to elucidate its downstream pathways. 
 
1 Portions of this chapter were previously published in Arteriosclerosis, Thrombosis, and 
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By performing overexpression (126-OE) and knockdown (126-KD) of miR-126 in 
HLMVEC, we found that high levels of miR-126 were associated with reduced proliferation, 
weak tube formation, and increased apoptosis while the opposite were observed with 126-KD. 
During cigarette smoking (CS) exposure, 126-OE did not exert additive effects to CS-induced 
cell apoptosis and angiogenesis inhibition whereas 126-KD reduced cell death and the impaired 
angiogenesis and barrier function caused by CS. To further understand the downstream 
signaling pathways regulated by miR-126, we utilized bioinformatics tools including RNA-
sequencing and pathway analyses to show that at the transcriptomic level, miR-126 drove an 
anti-angiogenic and pro-apoptotic profile in HLMVEC. We confirmed using Western blot that 
miR-126 was a potent inhibitor of mTOR activity despite imposing no effect on VEGF signaling. 
We found that solute carrier family 7 member 5 (SLC7A5) and disintegrin and metalloproteinase 
domain-containing protein 9 (ADAM9) were direct targets of miR-126 in HLMVEC and the effect 
of miR-126 on cell proliferation, but not apoptosis, was dependent on the SLC7A5-mTOR axis.  
Our findings suggested a cell type-specific role of miR-126 in primary human lung 
microvascular cells involving negative regulation of targets and pathways essential for 
angiogenesis and cell survival, which may in turn have potential implication on the pathogenesis 
of microvasculature-based lung diseases and provide basis for site-specific therapeutic 
treatment.  
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CHAPTER I 
INTRODUCTION 
MicroRNA-126 
MicroRNA biogenesis and function 
MicroRNAs (miRNAs) are a family of small (~22nt) and highly-conserved non-coding 
RNAs that regulate gene expression via post-transcriptional silencing1. In humans, the majority 
of miRNAs reside in intronic regions and their expressions usually parallel with their host genes. 
The transcription of miRNAs is carried out by RNA polymerase II (Pol II), leading to the 
production of a long (>1kb) primary transcripts known as pri-miRNA. A typical pri-miRNA stem-
loop structure contains two single stranded RNA segments on the 5’ and 3’ sides, a 33-35bp 
stem, and a terminal loop where the mature miRNA is embedded (Fig I-1, Step 1). Following 
transcription, pri-miRNA is processed by Drosha, a nuclear RNase III-type endonuclease, and 
its co-factor DGCR8 to give rise to a 60-70 nucleotide (nt) stem-loop intermediate called the 
precursor miRNA (pre-miRNA, Fig I-1, Step 2). The cleavage by Drosha leaves the pre-miRNA 
a 5’ end phosphate and a ~2-3nt 3’ end overhang, which is important for the determination of 
miRNA specificity in the subsequent maturation process2. The transportation of pre-miRNA into 
the cytoplasm is mediated by exportin-5, a double-stranded RNA (dsRNA) binding protein, in 
GTP dependent manner3 (Fig I-1, Step 3). In the cytoplasm, the 5’ phosphate and 3’ overhang 
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of pre-miRNA are quickly recognized by Dicer, a cytosolic RNase III-type endonuclease4, which 
then cleaves off the stem-loop structure, giving rise to a small RNA duplex consist of the mature 
miRNA sequence as well as a complementary fragment from the opposite arm (Fig I-1, step 4). 
This RNA duplex is subsequently associated with Argonaute 2 (AGO2) protein5 to form a RNA-
induced silencing complex (RISC) (Fig I-1, step 5-6). During RNA duplex loading, AGO2 
preferentially selects for a guide strand, which usually possesses a uracil (U) at the nucleotide 
position 1 and has a relatively unstable 5’ terminus6. Meanwhile, the opposite strand, also 
known as passenger strand, is generally degraded, resulting in a strong dominance of the guide 
strand in the cytoplasmic miRNA pool.  
However, the strand selection by AGO2 is not completely restricted to the guide strand, 
and thus the passenger strand can be selected at various frequencies depending on their 
sequences and stability. It is notable that although the passenger strands are competent at RNA 
silencing, they are believed to be less potent compared to the more prominent guide strands7, 8. 
In order to differentiate the two strands, the nomenclature miRNA (guide) / miRNA* (passenger) 
was first used, but later replaced by the expression of -3p/-5p due to the discoveries that both 
strands could be functional, and some might even be of equal stability and abundance9. This 
alternative strand selection, termed “arm switching”, is often observed when comparing miRNA 
expressions at different developmental stages as well as in different tissue types 8, 10, 11. 
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miRNA guides the RISC complex to its target via complementary base-pairing, and 
subsequently, miRNA downregulates its target gene expression by one of the two mechanisms: 
RNA degradation or translational inhibition (Fig I-1, step 7). The majority of miRNA binding sites 
reside in the 3’-untranslated regions (UTRs) of messenger RNAs (mRNA), and the 
complementarity between the miRNA seed sequence, which is located at the 2-7 position from 
the 5’ end of the miRNA, and the 3’-UTR binding site determines the suppression mechanism12. 
Perfectly matched miRNA seed:3’-UTR duplex leads to direct mRNA cleavage by AGO2 
whereas insufficient pairing leads to translational interference by slowing or stalling ribosomes. 
Building on the base-pairing mechanism of miRNA-mediated gene regulation, bioinformatic 
tools, such as TargetScan and MiRDB13-15, have been developed to identify potential miRNA: 
target interactions. These tools have since contributed tremendously to the characterization of 
miRNA functions. It has been estimated that more than 60% of human genes contain at least 
one miRNA binding site16; therefore, it is not surprising that miRNAs are involved in the 
regulations of nearly all biological processes. Deficiencies of proteins involved in miRNA 
maturation  
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Figure I- 1. Biogenesis of microRNA.  
A schematic of microRNA (miRNA) biogenesis adapted from Bartel D et al., 20041. miRNA is 
transcribed by RNA polymerase II (Pol II) in the nucleus and processed by nuclear 
endonuclease Drosha into precursor-miRNA before being transported into the cytoplasm by 
exportin5. In the cytoplasm, the stem-loop structure of pre-miRNA is cleaved by cytoplasmic 
endonuclease Dicer. Facilitated by helicase, one strand of the pre-miRNA duplex is incorporated 
into the RNA-induced silencing complex (RISC), which suppresses mRNA expression by 
transcriptional repression or direct degradation.  
  
mRNA
degredation
Translational 
repression
7
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such as Drosha, Dicer, and AGO2 are embryonic lethal, demonstrating that miRNAs are critical 
during development17-19. In adults, miRNAs persist to regulate essential biological processes 
such as cell growth, cell differentiation, angiogenesis, and tumor growth1, 12.  
miR-126 in angiogenesis 
In contrast to vasculogenesis in which endothelial progenitors (angioblasts) differentiate 
into endothelial cells and form blood vessels de novo, angiogenesis is defined as the 
development of new vessels from pre-existing vasculature20. Under the stimulation of 
angiogenic factors such as vascular endothelial growth factor (VEGF) and fibroblast growth 
factor (FGF), endothelial cells secret several proteases (i.e. matrix metalloprotease, MMP) that 
break down the vascular basement membrane to enable subsequent invasion through the 
extracellular matrix (ECM)21. Endothelial cells from the existing vessel then migrate, usually 
following a VEGF-A gradient, proliferate and eventually differentiate into a lumen-containing 
vessel22. As the vessel matures, endothelial cells continue to secrete ECM, which forms a new 
basement membrane, and platelet-derived growth factor (PDGF), which recruits pericytes and 
smooth muscle cells to further stabilize the newly formed blood vessel21. Angiogenesis is 
required for embryonic development and is crucial for tissue repair in adult. Growth factors 
involved in the process of angiogenesis, such as VEGF, FGF, and PDGF, are indispensable for 
angiogenesis as deficiencies in these factors or loss of their receptors led to embryonic lethality 
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and severely impaired endothelial function in in vitro studies23-26. Angiogenic factors function by 
interacting with their respective membrane tyrosine receptors, which upon activation, initiate 
intracellular signaling cascades that critically regulate endothelial cell survival and function. 
Molecules that participate or regulate growth factor receptor activity or their downstream 
signaling pathways have been intensely studied and targeted for the treatments of diseases 
involving dysregulated angiogenesis such as cancer, diabetes, and rheumatoid arthritis20.  
Encoded in intron 7 of epidermal growth factor-like domain 7 (EGFL7), microRNA-126 
(miR-126) is enriched specifically in the endothelial cells throughout the body, with the greatest 
expression in highly vascularized organs such as the lung and the heart27. Other cell types that 
express miR-126, albeit at comparatively lower levels, include endothelial progenitors (EPC)28, 
29, hematopoietic stem cells30, 31, and various type of cancer cells.32 In the mature miRNA pool in 
human endothelial cells, both the primary strand (3p) and the passenger strand (5p) of miR-126 
are present and functionally active27, 33 (Fig I-2). Although in the endothelial cells, the average 
expression of miR-126-5p is only found at ~25% of that of miR-126-3p27, 34. Hereafter, the term 
miR-126 will be used to refer to the 3p strand and miR-126-5p for the 5p strand.  
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Figure I- 2. Structure of the mouse Egfl7 gene and precursor miR-126.  
A schematic showing the structure and sequence of precursor miR-126 (pre-miR-126), which 
contains both the 3p and 5p strands of mature miR-126. miR-126 is encoded in intron 7 of Egfl7 
gene and is conserved between human and mice. Adopted from Wang S et al., 200827.  
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miR-126 is critical for the maintenance of embryonic vascular integrity and angiogenesis. 
Expression of miR-126 is induced as early as E10.5 in the mouse embryo  
and maintained at high level throughout development35. Two independent research groups 
reported in mice27 and in zebra fish35, respectively, that miR-126 knockout (KO) mutants 
exhibited ~40% lethality and displayed profound vascular defects including smaller or collapsed 
arterial lumen and extensive edema and hemorrhage as a result of impaired vascular integrity27. 
These abnormalities were associated with reduced endothelial cell proliferation and tight 
junction, but not cell apoptosis. In addition, miR-126 did not control endothelial lineage 
commitment since the comparison of differentiation outcomes between control and miR-126 KO 
mouse embryonic stem cell lines showed no difference in the expression of endothelial lineage 
markers such as Flk1, Tie2, and CD3135, which indicates that miR-126 may not regulate 
developmental vasculogenesis.  
The surviving miR-126 KO neonates appeared to be normal to adulthood, implying that 
miR-126 may not be required for vascular maintenance in adult27. However, these mice 
exhibited delayed corneal angiogenesis in response to VEGF27 as well as mild choroidal 
endothelial atrophy36. Additionally, they were more prone to death under stress conditions like 
myocardial infarction, which implicates a role of miR-126 in regulating endothelial response to 
stress and disease conditions27. Indeed, other research groups have shown that decreased 
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miR-126 is associated with reduced vascular repair and density during pulmonary hypertension 
and diabetes37, 38. Local injection of miR-126 synthetic mimics after ischemic injury improved 
blood flow in mouse limb39. 
The effect of miR-126 on vascular development is primarily mediated through 
disinhibitions of the VEGF and FGF signaling cascades40, namely via the ERK and AKT 
pathways (Fig I-3). Sprouty-related EVH1 domain-containing protein 1 (SPRED1) and 
phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2), are direct targets of miR-12627. 
SPRED1 is a tyrosine kinase binding protein that directly interacts with Ras and Raf. Binding of 
SPRED1 prevents Ras from phosphorylating Raf, which is upstream of ERK and in turn leads to 
suppression of the MAPK/ERK signaling cascade41. PIK3R2 (p85b) is an inhibitory subunit of 
phosphoinositide-3-kinase (PI3K), which critically regulates the growth factor-mediated 
activation of PKB/AKT signaling pathway42. In human umbilical vein endothelial cells (HUVEC), 
the expression of SPRED1 and PIK3R2 were significantly upregulated during miR-126 inhibition 
and simultaneous inhibition of SPRED1 or PIK3R2 during miR-126 inhibition was able to 
partially rescue the defect in VEGF-mediated ERK or AKT activation, respectively27, 35. 
Knockdown of SPRED1 also improved angiogenic capacity of aortic ring isolated from miR-126 
KO mice and wound healing of HUVEC transfected with antisense miR-126 inhibitors27. 
However, it remains unknown whether the profound effect of miR-126 on vascular development 
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in vivo is indeed mediated through SPRED1 and PIK3R2 as study using transgenic mouse 
model has not been reported. Furthermore, given that both alleles of miR-126 were deleted in 
miR-126 KO studies in vivo and that studies performed in vitro predominantly focused only on 
the 3p primary strand, the contribution of miR-126-5p to vascular development is largely 
unclear. 
Other targets known to mediate the angiogenic effect of miR-126 include vascular cell 
adhesion molecule-1 (VCAM-1) and regulator of G protein signaling 16 (RGS16). By reducing 
the expression of VCAM-1, miR-126 suppresses the recruitment of leukocytes and protects the 
endothelium from inflammatory damage43. During hyperlipidemia, apoptotic endothelial cells can 
release miR-126-containing membranous vesicles, which are taken up by neighboring 
endothelial cells and lead to downregulation of RGS1644, a negative regulator of CXCR4 that 
plays an essential role in the recruitment of EPC during tissue repair45. 
  
 
 11 
 
Figure I- 3. miR-126 signaling via the vascular endothelial growth factor signaling 
pathway.  
A schematic showing mechanism proposed by Fish JE and colleagues that miR-126 promotes 
angiogenesis and maintains vascular integrity by targeting sprouty-related EVH1 domain-
containing protein 1 (SPRED1) and phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2), 
which are downstream of the vascular endothelial growth factor (VEGF) signaling pathway. 
Adopted from Fish JE et al. 200835. 
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miR-126 in post-developmental angiogenesis 
The transcriptional and functional profiles of endothelial cells can differ significantly 
depending on their organ or tissue of origin, and as such endothelial cells are considered highly 
heterogenous46. Since there has not been tools available to target and study the role of miR-126 
in a particular vascular bed in vivo (arterial, microvascular, or venous), primary human 
endothelial cells isolated from different vasculatures such as the pulmonary capillary, pulmonary 
artery, umbilical vein, and aorta were cultured in vitro to tackle this important question. 
Interestingly, these in vitro studies demonstrated that miR-126 can play either angiogenic or 
anti-angiogenic role. It has been shown in human aortic endothelial cells (HAEC)27, 47 and 
coronary artery endothelial cells (HCAEC) 45 that similar to its role during vascular development, 
miR-126 promotes cell migration and angiogenic capacity. As mentioned previously, inhibition of 
miR-126 decreased HUVEC migration and dampened VEGF-induced activation of ERK and 
AKT signaling due to upregulation of SPRED135. However, it was reported at the same time that 
miR-126 inhibited proliferation of HUVEC cultured in complete growth medium, suggesting that 
the role of miR-126 may differ when different growth factors are present35. In contrast, two 
independent groups reported similar observations that by targeting VEGF-A, local injection of 
miR-126 synthetic mimics inhibited retinal neovascularization48, 49, a pathological process 
characterized by excessive choroidal microvascular angiogenesis commonly caused by 
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diabetes50. miR-126 was also found to be downregulated in RF/6A, a monkey choroid 
endothelial cell line, under hypoxia condition leading to increased VEGF-A expression51. 
Furthermore, it was shown in adult late EPC that miR-126 overexpression led to reduced EPC 
proliferation whereas miR-126 inhibition enhanced EPC proliferation and angiogenic capacity as 
indicated by increased sprouting29. These results coincided with our findings that miR-126 
inhibited the proliferation and tube formation of primary human lung microvascular 
endothelial cells (HLMVEC) by targeting mTOR signaling pathway34. Although the exact 
mechanism that determines the angiogenic or anti-angiogenic function of miR-126 remains 
undefined, it is likely associated with cell type-specificity and involves differential regulations of 
distinct sets of mRNA targets, which is characteristic of miRNA regulation1, 52. 
miR-126 in cancer 
The expression and function of miR-126 have been extensively studied in cancer. In 
contrast to its complex role in the endothelium, miR-126 predominantly acts as a tumor 
suppressor in cancer cells. The expression of miR-126 is consistently decreased across multiple 
cancer types including breast, lung, prostate, and pancreatic cancers32. The effects of miR-126 
in cancer are mediated through direct regulation of targets related to cell growth, migration, and 
adhesion. For example, in breast cancer and non-small cell lung cancer cell lines, lentivirus-
mediated overexpression of miR-126 significantly reduced VEGF-A expression53, 54, which led to 
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severe cell cycle arrest and growth inhibition both in vitro and in vivo. The disintegrin and 
metalloproteinase domain-containing protein 9 (ADAM9), another verified target of miR-126, 
was upregulated in pancreatic and gastric cancer as a result of decreased miR-12655, 56. As 
indicated by its name, ADAM9 is a member of the transmembrane metalloprotease family that 
plays an essential role in growth factor signaling as well as cell-cell and cell-matrix interaction57. 
The proteolytic capacity of ADAM9 enables shedding and activation of membrane-tethered 
growth factors and ligands58. In esophageal squamous carcinoma cells, overexpression of miR-
126 inhibits cancer cell motility and proliferation by suppressing the ADAM9-EGFR-AKT 
signaling axis55, 56. In addition, the transmembrane domain of ADAM9 can promote cell migration 
by directly interacting with integrin b1 in the ECM59. Since nutrient availability is indispensable 
for cancer growth, miR-126 was shown to inhibit lung cancer cell proliferation by restricting 
essential amino acid (EAA) uptake via direct inhibition of solute carrier family 7 member 5 
(SLC7A5, also known as LAT1)60, an amino acid transporter critical for extracellular leucine 
uptake61. In gastric cancer, the growth arrest caused by miR-126 can be rescued via 
simultaneous overexpression of SLC7A562. Other targets found to be regulated by miR-126 in 
cancer cells include CRK and IRS-1, both of which lead to increased cell mobility and 
proliferation when activated63-65. Together, these results indicate a negative role of miR-126 in 
tumor development. However, as there has not been study focused specifically on the cancer 
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vasculature, the role of miR-126 during tumor angiogenesis remains unknown.   
Strand-specific function of miR-126 
Although not as well-studied relative to miR-126 (3p), miR-126-5p is fully functional and 
can work either independently or in collaboration with miR-126. For instance, both miR-126 and 
miR-126-5p were found to be decreased in breast cancer66, leading to upregulation of a shared 
target SDF-1, which recruited mesenchymal stem cells to the site of tumor to create a growth-
promoting microenvironment. Restoration of miR-126 and miR-126-5p significantly reduced 
tumor growth and metastatic capacity66. Deletion of miR-126 gene, which led to loss of both the 
3p and 5p alleles, was shown to impair carotid artery angiogenic repair in a murine 
hyperlipidemia model designed to mimic atherosclerosis33. Interestingly, at the nonpredilection 
site, the anti-angiogenic phenotype could be rescued only by restoring miR-126-5p levels, which 
suppressed DLK1, a noncanonical inhibitor of NOTCH1. This suggests that in certain tissues, 
miR-126-5p can play a more dominant role in angiogenesis regulation compared to the 3p 
counterpart.  
Regulation of miR-126 expression 
It is believed that the transcription of miR-126 is regulated under the same promoter as 
EFGL7, supported by the fact that miR-126 expression largely mirrors that of EGFL7 during 
development35, 67; It is known that ETS1 and ETS2, a set of transcription factors that play an 
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important in regulating endothelial cell function, promote miR-126 expression68. Loss of ETS1/2 
in HUVEC led to a significant decrease in the expression of both EGFL7 and miR-126. Other 
transcription factor binding sites upstream of EGFL7 transcription start site include GATA1/2 and 
KLF268, 69. During embryonic aortic arch sprouting, the mechano-sensitive transcription factor 
KLF2 is upregulated in response to blood flow and results in expression of miR-126 to promote 
VEGF signaling67 . To note, this effect of KLF2 on miR-126 was not observed in adult endothelial 
cells70. Additionally, EGFL7 is susceptible to DNA methylation. In diseases such as cancer and 
pulmonary hypertension, decreased miR-126 levels were found to be associated with EGFL7 
hypermethylation38, 56. The mechanisms involved in changes in miR-126 levels during most 
physiological or pathological processes remain largely unknown.  
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Lung Endothelial Cells  
Endothelial heterogeneity 
Endothelial cells comprise the inner lining of blood vessels throughout the vascular 
system. Instead of serving as inert conduits, endothelium plays important roles in processes 
such as vasomotor tone regulation, coagulation and hemostasis, immune cell trafficking, fluid 
permeability, and tissue repair and regeneration71. Developmentally, endothelial cells are 
derived from the mesoderm angioblasts and surface proteins expressed across all vascular 
beds, such as platelet/endothelial cell adhesion molecule-1 (PECAM-1, also known as CD31) 
and vascular endothelial (VE)-cadherin, have been used as markers to identify endothelial cells. 
The vascular system can be anatomically divided into two compartments: the macrovascular 
bed that includes the arterial and venous networks, and the microvascular bed that consists the 
capillaries within different tissues. Endothelial cells from different vascular beds as well as from 
different tissue- and organ- origins exhibit distinct properties at both molecular and functional 
levels46. In a study where 52 cultured endothelial cells purified from different vascular beds and 
tissues were profiled, highly distinguishable gene clustering patterns were found between 
microvascular- and macrovascular- endothelial cells. Divergent gene expression profiles were 
also found within the microvascular cell groups from different tissues, highlighting the 
contribution of local microenvironment to endothelial cell diversity72. 
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Lung structure 
The primary function of mammalian lung is to provide sufficient surface area for gas 
exchange, a passive process in which environmental oxygen diffuses into the bloodstream while 
carbon dioxide is simultaneously released back to the atmosphere.  
Pulmonary airways arise from the trachea and typically undergo 23 generations of 
bifurcations until eventually reaching the alveolus, the terminal structure where gas exchange 
takes place. The lung vasculature goes through similar bifurcation process, originating from one 
single artery and, after about 28 generations of dichotomous branching, ultimately giving rise to 
the pulmonary capillary networks tightly surrounding the alveoli73, 74. Inner surface of the 
alveolus is lined with a thin layer of squamous epithelium and its basement membrane, which is 
often fused with the basement membrane of the surrounding capillaries to allow rapid gas 
exchange. It is estimated that the thickness of human alveolar membrane is less than 0.1 µm75, 
76. This specialized structure of the alveolar-capillary membrane, together with the fractal 
structure of pulmonary airway and vasculature, are intrinsically designed to facilitate gas 
exchange by allowing maximal surface area and relatively easy passage of gas. 
In addition to the pulmonary vasculature, the lung is also perfused by the bronchial 
circulation which originates from the aorta or intercoastal arteries73. The bronchial arteries are 
categorized as intra-pulmonary vessels, which perfuses the airway from the tracheal carina to 
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terminal bronchioles, the walls of pulmonary artery and vein, and pulmonary pleura, and as 
extra-pulmonary vessels, which carry blood to the esophagus, lobar bronchus, and hilar lymph 
nodes. Beside delivering oxygen and nutrients, bronchial circulation plays an important in 
thermoregulation and humidification of ambient air76. However, in this chapter, we will mainly 
focus on the pulmonary circulation. 
Pulmonary vascular endothelial cells 
Pulmonary artery endothelial cells and microvascular endothelial cells are highly 
specialized cell types with distinct features. In addition to serving as a critical component of the 
alveolar-capillary membrane, pulmonary microvascular endothelial cells form a tight barrier to 
prevent blood fluid extravasation that leads to alveolar flooding and edema and thereby 
reduction in gas exchange77. In rat lung, the fluid filtration rate is 28-fold higher in the pulmonary 
artery than in the microvasculature78. Lung microvascular endothelial cells also express higher 
levels of junction proteins such as N-cadherin, CD166, and zonula occludens-2 (ZO-2)79. In 
contrast, proteins associated with the function of larger vessels are preferentially enriched in the 
arterial endothelial cells. For example, endothelial nitric oxide synthase (eNOS), an enzyme 
which produces nitrogen oxide that acts as a potent vasodilator, was found to be highly 
expressed in the pulmonary arterial endothelial cells relative to their microvascular 
counterparts80, likely in order to maintain the low pulmonary arterial tone.  
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The lung microvascular and arterial endothelial cells may be relatively well distinguished 
in vivo using plant lectins. Griffonia simplicifolia lectin exclusively binds to the a-galactose 
expressed on the microvascular endothelial cells whereas Helix pomatia lectin binds only to the 
a- and b-acetyl-galactosamine expressed on the pulmonary artery endothelial cells81. Utilization 
of this technique allowed purification of these two distinct cell types from lung tissue digest and 
greatly facilitated further comparative studies in vitro. Cultured microvascular endothelial cells 
persisted to display greater barrier function78, 82, suggesting that epigenetic modification may be 
involved to drive vascular bed-specific endothelial functions. While increased intracellular Ca2+ 
level led to higher permeability in pulmonary arterial endothelial cells, it was not sufficient to 
cause barrier disruption to the microvascular cell monolayer82, suggesting a distinct Ca2+-
independent mechanism for microvascular barrier regulation. Moreover, relative to the 
pulmonary artery endothelial cells, microvascular endothelial cells exhibited significantly higher 
proliferative rate and angiogenesis capacity83. In fact, it has been shown that a subset of the 
lung microvascular endothelial cells may function as EPC84. In addition, the pulmonary 
microvascular endothelium plays an essential role in the maintenance of lung homeostasis and 
tissue repair. Residing in proximity to alveolar epithelial cells and mesenchymal cells, lung 
microvascular endothelial cells critically support other lung cell types by producing molecules 
and growth factors important for their survival and function85. For example, the restoration of 
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alveolar epithelial cell after experimental pneumonectomy was dependent on MMP14 secreted 
by the alveolar microvascular endothelial cells, which allowed unmasking of EGF-like ligand 
crucial for epithelial cell growth86. In turn, maladaptive microvascular niches can promote 
fibrosis87. In human, dysfunctional pulmonary microvasculature is associated with the 
pathogenesis of various lung diseases including pulmonary hypertension, lung fibrosis, acute 
respiratory distress syndrome, and emphysema88.    
Lung vasculature in COPD 
Cigarette smoking (CS) is a worldwide public health issue that serves as the major 
cause of Chronic Obstructive Pulmonary Disease (COPD), the fourth leading cause of death in 
the United States89. One main phenotype of COPD is emphysema, which is characterized by 
irreversible loss of lung alveolar structure due to lung endothelium and epithelium apoptosis, 
chronic inflammation and impaired capacity in pulmonary vascular repair90. The important role of 
endothelial cells during the pathogenesis and development of emphysema was suggested by 
multiple studies showing that blockade of VEGF signaling, a pathway crucial for endothelial cell 
survival, was sufficient to cause emphysema-like lung disease in both mouse and rat91, 92. The 
mechanisms of cigarette smoking induced endothelial cell death have been shown to be related 
to oxidative stress, sphingolipid imbalance and cellular senescence90. However, despite the 
potent regulatory effect of miR-126 on VEGF signaling and endothelial cell function, it remains 
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unknown whether miR-126 is involved in CS-induced endothelial cell injury. 
Mammalian Target of Rapamycin Signaling and Function 
Mammalian Target of Rapamycin 
The mammalian target of rapamycin (mTOR) integrates a diverse set of environmental 
signals such as nutrients and growth factors and controls eukaryotic cell growth. By sensing the 
availability of nutrients, mTOR coordinates between the synthesis and breakdown of 
biomolecules, including proteins, lipids, and nucleotides, which are fundamental for cell survival 
and proliferation. Abnormalities in mTOR and its downstream signaling pathways are associated 
with a wide range of diseases, including cancer, diabetes, neurodegeneration and aging93.  
mTOR is a conserved 289-kDa serine/threonine protein kinase that belongs to the PI3K-
related kinase family. In mammalian cells, mTOR forms two distinct complexes known as mTOR 
complex 1 (mTORC1) and mTOR complex 2 (mTORC2)94 (Fig I-4A-B). The core components of 
mTORC1 are mTOR, mammalian lethal with SEC13 protein 8 (mLST8) and the regulatory-
associated protein of mTOR (RAPTOR). It is believed that mLST8 stabilized the mTOR kinase 
domain while RAPTOR, a defining factor of mTORC1, is pivotal for mTOR function and 
lysosomal localization95, 96. Additionally, RAPTOR binds to the proline-rich AKT substrate 40kDa 
(PRAS40), an insulin-responsive inhibitor of mTORC1. When rapamycin is present, PRAS40, 
together with FKBP12-rapamycin, prevent entry of mTOR substrate into the kinase domain and 
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thereby significantly inhibits mTOR activation even in the presence of nutrients97. While 
mTORC2 shares with mTORC1 the same components including mLST8 and DEP-domain-
containing mTOR-interacting protein (DEPTOR), a common inhibitor of both mTOR complexes, 
mTORC2 is distinguishable from mTORC1 by the presence of the rapamycin-insensitive 
companion of mTOR (RICTOR)98. As suggested by its name, RICTOR blocks the binding of the 
inhibitory FKBP12-rapamycin to the kinase active site of mTOR, rendering mTOCR2 insensitive 
to acute inhibition by rapamycin. As a scaffold protein, RICTOR also interacts with Protors and 
mSIN1.  
The distinct components of mTORC1 and mTORC2 give rise to separate functions of 
these two complexes. mTORC1 mainly controls cell growth, protein translation99, and ribosome 
biogenesis whereas mTORC2 regulates cell survival and cytoskeletal behaviors100. Here, we will 
specifically focus on mTORC1 (hereafter referred as mTOR).  
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Figure I- 4. Structures of mTOR and targets of mTORC1.  
A-B. Structures of mammalian target of rapamycin complex 1 and 2 (mTORC1 and mTORC2). 
C. Effectors downstream of mTOR that promotes protein synthesis or protein breakdown 
through autophagy and lysosome biogenesis. Solid box indicates positive regulation. Box with 
dashed line indicates negative regulation. Adapted from Liu GY and Sabatini DM., 202093.  
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mTOR signaling pathway and cellular function 
mTOR controls multiple cellular processes to ensure that the metabolic demand of 
growing cells is met. The biological effects of mTOR are executed by phosphorylating 
substrates involved in the synthesis of proteins, lipids, nucleotides, and ATPs. The two major 
substrates of mTOR related to cell growth are the eukaryotic initiation factor 4E-binding protein 
(4E-BP) and p70 S6 Kinase (S6K)101 (Fig I-4C). 4E-BP is an intrinsic suppressor of translation 
because it binds and sequesters initiation factor 4E (eIF4E) from forming the eIF4F cap-binding 
complex required for mRNA translation102. Phosphorylation of 4E-BP by mTOR releases eIF4E 
and thereby promotes mRNA translation. The activation of S6K requires a dual-phosphorylation 
by mTOR at T389 and by pyruvate dehydrogenase kinase 1 (PDK1) at T229103. Once fully 
activated, S6K can proceed to phosphorylate a wide variety of substrates. S6K enhances mRNA 
translation by phosphorylating ribosomal protein S6104, a 40S ribosome subunit commonly used 
to indicate S6K activity under experimental settings. S6K also promotes protein synthesis by 
direct phosphorylation of translation initiation factor eIF4B105 and upstream binding factor 
(UBF)106, which enhances the activities of RNA Pol I and III. In addition to protein synthesis, S6K 
promotes lipid and nucleotide productions through activating factors such as PPARg and 
ATF4107, 108, which are transcription factors that control the expression of genes related to lipid 
homeostasis and nucleotide biosynthesis, respectively. Interestingly, S6K has also been shown 
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to be crucial for angiogenesis. In an adenovirus VEGF-A expressing mouse model, 
simultaneous loss of S6K1 significantly reduced angiogenesis109. However, the effect of mTOR 
on angiogenesis is not well-characterized and therefore the underlying mechanism remains 
unclear.  
In order to prevent the premature breakdown of newly synthesized molecules, mTOR 
intrinsically serves as an inhibitor of macroautophagy110 (hereafter referred to as autophagy, Fig 
I-4C), a highly conserved process in which cytoplasmic contents are being degraded and 
recycled by lysosomes. This inhibitory function of mTOR on autophagy is carried out through 
direct phosphorylation of mTOR substrate UNC-51-like kinase 1 (ULK1), autophagy-related 
gene 13 (Atg13) and transcription factor EB (TFEB), which are critically involved in the process 
(ULK and Atg13) and the regulation (TFEB) of autophagy99. Autophagy is a step-wise process 
that starts with the formation of phagophore, an isolation membrane derived from the 
endoplasmic reticulum and/or Golgi111. Interaction of ULK1 and Atg13 is required for 
phagophore formation and phosphorylation of ULK1 and Atg13 by mTOR prevents this 
interaction, leading to autophagy initiation inhibition112. In contrast, when mTOR function is 
inactivated, formation of the ULK1-Atg13-FIP200 complex allows the phagophore to continue to 
develop in an Atg 5-Atg12-dependent manner. In the meantime, microtubule-associated protein 
light chain 3 (LC3B) is processed into LC3B-I and then into LC3B-II, which is later integrated 
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into the extending phagophore membrane. LC3B is the only currently known protein to 
associate specifically with autophagosome membrane and therefore serves as a key 
measurement for cell autophagy status in experimental settings113. Engulfment of cargoes by 
autophagosome is generally considered to be non-selective. Although there has been 
accumulating evidence showing that proteins or organelles can be selectively sequestered. One 
well-characterized mechanism involves LC3B, which recognizes and interacts with proteins and 
organelles expressing sequestosome 1 (p62 or SQSTM1), leading to selective autophagosome 
uptake114. Once fused with the lysosomes, cargoes contained in the autophagosomes are 
degraded by lysosomal proteases, and the amino acids produced are released back to the 
cytoplasm to be re-used. To note, because p62 is usually degraded with other cargoes in the 
lysosome, its expression levels during autophagy are often used as an indicator of successful 
autophagosome-lysosome fusion, known as the autophagic flux. Bafilomycin, a potent inhibitor 
of autophagy that suppresses lysosome acidification, can significantly increase cytosolic p62 
expression115. mTOR can regulate lysosomal formation and function by phosphorylating TFEB, 
a transcription factor that controls genes involved in lysosome biogenesis. When mTOR is 
active, it inhibits lysosome production and function by containing TFEB in the cytoplasm116. 
Located downstream of mTOR, autophagy is therefore sensitive to nutrient availability 
and coordinates with mTOR to balance between anabolic and catabolic states in the cell and to 
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adapt to stress conditions such as nutrient deprivation. However, recent discoveries have found 
that autophagy can be initiated independent of mTOR. These pathways, although less well-
characterized, involve the inositol 1,4,5-trisphosphate (IP3)/ cAMP/Epac or the JNK1/Beclin-
1/PI3KC3 pathway110, 113. 
Regulation of mTOR function 
Since mTOR is a pivotal hub for integrating different environmental signals, it is 
important to ensure that mTOR can only be activated when all requisites for cell growth 
including nutrient, growth factors, and ATP are fulfilled. Signaling cascades downstream of 
growth factors, oxygen and ATP sensors converge on tuberous sclerosis complex (TSC) for 
mTOR activation117 (Fig I-5). TSC complex, consists of TSC1, TSC2 and TBC1D7118, acts as a 
GTP-activating protein (GAP) for the small GTPase Ras homologue enriched in brain (Rheb), 
which localizes at the lysosomal membrane and directly activates mTOR in its GTP-bounds 
state119. For example, when energy is limited, high AMP/ATP ratio leads to activation of 5' AMP-
activated protein kinase (AMPK) that phosphorylates TSC at its activating site. Active TSC then 
converts Rheb-GTP to Rheb-GDP and in turn suppresses mTOR120 activity. In the presence of 
growth factors such as insulin, insulin receptor activates its downstream effector PI3K, which 
then phosphorylates TSC at its inactivating site, leading to its dissociation and disinhibition of 
Rheb121. However, growth factors alone have little or no effect on mTOR122. This is because the 
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colocalization of mTOR at the lysosome membrane is required for Rheb-mediated activation 
and the translocation of mTOR is regulated by amino acid through a mechanism independent of 
TSC123. The mTOR localization to lysosome is controlled by the Rag GTPase heterodimers124. 
Amino acids convert Rag to its active state containing GTP-bound RagA/B and GDP-bound 
RagC/D, which anchors mTOR to the lysosomal membrane where it can be activated by 
Rheb125. As such, amino acid abundance serves as a prerequisite for growth factor mediated-
mTOR activation and together this exquisite mechanism ensures that mTOR only allows cell 
growth when both growth factors and nutrients are available (Fig I-5).  
Amino acid transporters 
While growth factors interact with their specific membrane receptors, extracellular amino 
acids enter the cell through membrane amino acid transporters. The movement of amino acids 
through transporters are usually coupled with transportations of ions such as Na+, K+, and H+ or 
with other amino acids by symporters (co-transport) or antiporters (exchange)126. So far there 
are 6 major transporter families discovered that are encoded by the solute carrier (SLC) gene 
superfamily including SLC1, SLC6, SLC7, SLC36, SLC38, and SLC43. These transporters 
feature multi-transmembrane domains surrounding a central pore and amino acid binding sites 
that often specifically recognize a set of structurally similar amino acids126-128. SLC7A5, which 
forms a transporter complex with its stabilizing subunit 4F2 cell surface antigen heavy chain 
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(4F2hc, encoded by SLC3A2), is a main transporter for large neutral amino acids, notably 
leucine128, 129. SLC7A5 catalyzes the import of leucine in rapid exchange of L-glutamine, which 
is usually pumped out within 1-2 min130. The intracellular L-glutamine pool is replenished by 
SLC1A5, which mediates the transportation of L-glutamine and other small neutral amino acids 
in a Na+-dependent manner131. Cells void of L-glutamine by amino acid starvation are not able 
to import leucine via SLC7A5130, suggesting that SLC7A5 functions downstream of SLC1A5 and 
that the maintenance of intracellular L-glutamine pool is crucial for leucine uptake.  
Upon entry, leucine is sensed by the intracellular cellular amino acid sensor Sestrin2132, 
133 and results in its dissociation from GATOR2, leading to disinhibition of Rag GTPase and 
subsequent mTOR activation at the lysosomal membrane. mTOR activity is therefore highly 
sensitive to leucine and in turn L-glutamine levels. Inhibition of SLC7A5 or SLC1A5, both 
genetically and functionally, were able to severely reduce mTOR activity and inhibit cell growth. 
In addition, during amino acid deprivation, only the re-introduction of both leucine and L-
glutamine was able to reactivate mTOR130, stressing on the notion that the efflux of L-glutamine 
is rate limiting for the leucine-mediated mTOR activation. Factors that regulate SLC7A5 and 
SLC1A5 expressions remain poorly understood. It has been shown under hypoxia condition that 
the HIF2⍺	increases the expression SLC7A5 to upregulate mTOR activity134. Growth factor 
PDGF increases SLC7A5 expression135 whereas during starvation and stress conditions, 
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membrane SLC7A5 levels can be modulated through endocytosis136. SLC7A5 possesses a 
miR-126 binding site in its 3’-UTR and is confirmed to directly interact with miR-126 in various 
cancer cells61. Future studies are needed to determine whether miR-126 targets SLC7A5 and 
regulates mTOR signaling in endothelial cells.  
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Figure I- 5. Signaling pathways upstream of mTORC1. 
mTOR integrates environmental signals including growth factors (i.e. insulin), nutrients (i.e. 
amino acids and glucose) and energy status (i.e. ATP/AMP ratio) to control cell growth and 
autophagy. Entry of amino acids (left top), particularly leucine, through the SLC7A5 (also known 
as LAT1) – SLC3A2 antiporter complex activates mTORC1 via the Rag GTPase branch. On the 
contrary, growth factors, reactive oxygen species (ROS), and low energy state converge on the 
tuberous sclerosis complex (TSC), an intrinsic inhibitor of Ras homologue enriched in brain 
(Rheb), to regulate mTOR activity. Adopted from Jung CH et al., 2010137.  
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CHAPTER II 
METHODS2 
Reagents  
All reagents used are listed in Table II-1. 
Cell Culture  
Primary human lung microvascular endothelial cells (HLMVEC) were purchased from 
Lonza (CC-2527, LONZA) and maintained in microvascular endothelial growth medium EGM-2 
MV supplemented with growth factors and 5% FBS (CC-3202, LONZA). All experiments were 
performed in HLMVEC between passages 3 to 7, from at least three distinct donors (biological 
replicates). Donor information is listed in Table II-5. 
miRNA and siRNA Transfections 
We achieved miR-126 overexpression (126-OE) by transfecting HLMVEC at 80-90% 
confluency with miR-126-3p mimic (Dharmacon; 5nM for 16hrs), using lipofectamine RNAiMAX 
(Invitrogen). Similarly, we achieved miR-126 knockdown (126-KD) by transfection of antisense 
miR-126-3p inhibitors (Dharmacon; 5nM for 16hrs)(Fig II-1). For control condition, cells co-
transfected with non-targeting miRNA mimics and antisense inhibitors (5nM each,16hrs) were 
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used when comparing the effects of 126-OE and 126-KD in parallel. Alternatively, when studying 
only the effect of 126-KD, cells with a sole transfection of miRNA antisense inhibitor were used 
(5nM, 16hrs). These two control conditions showed no difference in their effects on miR-126 and 
SLC7A5 expressions, and S6 activity was affected in neither condition (Fig II-2). To achieve 
SLC7A5 knockdown, HLMVEC were transfected with siRNA targeting SLC7A5 gene 
(Dharmacon; 10nM, 16hrs), using a non-targeting siRNA as control (Dharmacon; 10nM, 16hrs). 
Transfection efficiencies were verified with RT-qPCR (Fig II-1) and corresponding protein 
expressions after knockdown were confirmed with Western Blot. Information for all miRNAs and 
siRNAs used are listed in Table II-2. 
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Figure II- 1. Transfection efficiencies of 126-OE, 126-KD, and 126-KD and siSLC7A5 co-
transfection. 
A. Relative miR-126 copy number in HLMVEC 24hrs after transfection with a mixture of miRNA 
non-targeting mimics and inhibitor controls (Ctrl), miR-126-3p mimics (126-OE), or antisense 
inhibitors (126-KD). *p<0.05; One-way ANOVA followed by Dunnett’s multiple comparisons test. 
B-C. Relative miR-126 (B) and SLC7A5(C) expressions in HLMVEC transfected with miR-126 
inhibitor, SLC7A5 siRNA or co-transfection of both, verified by RT-qPCR. Results presented as 
mean ± SEM; Each data point represents an individual experiment; At least three induvial 
donors were used per assay to eliminate contribution of donor-specific effects. 
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Figure II- 2. Off-target effects comparison between miRNA mimic negative control, 
antisense inhibitor negative control, and co-transfection of both.  
A-B. Expression levels of miR-126 and its target gene, SLC7A5, determined by RT-qPCR. C. 
SLC7A5 protein expression and S6 activity determined by Western blot. Left: representative 
Western blot image. Middle, right: densitometry quantification by normalizing SLC7A5 to vinculin 
and p-S6 to S6. Results presented as mean ± SEM; At least three induvial donors were used 
per assay to eliminate the contribution of donor-specific effects; No statistical significance was 
detected using One-way ANOVA followed by Dunnett’s multiple comparisons test.  
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Cell Proliferation 
Cell proliferation was determined by Ki67 immunofluorescence staining and by live cell 
counting. Following transfection with the indicated miRNA or siRNA, HLMVEC were seeded (0.3 
x 105 cells per well) onto fibronectin-coated (1µg/cm2) Nunc Lab-Tek II chamber slides 
(Cat#154534, Thermo Fisher) for immunostaining. After 24 hours, cells were washed with 
phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde for 30 min at room 
temperature. Ki67 was stained with Alexa 488-conjugated mouse-anti human Ki67 antibody (sc-
23900 AF488, Santa Cruz) and mounted with ProLong Gold with DAPI (P36931, Thermo 
Fisher). For Ki67 counting, 10-15 images were taken per condition in a blinded fashion with 
Nikon Eclipse Ti-U inverted microscope with Nikon Elements BR v4.30.02 software. Ki67 
positive cells and total number of cells (DAPI positive) were counted using Image J (1.52p) and 
the data were expressed as percentages of Ki67 positive cells. Representative images for 
figures were taken with Zeiss LSM700 Confocal with Zen Black software. For cell counting, 
transfected cells were seeded at 1.5 x 10 4 per well on a gelatin-coated 24-well plate. After 24, 
48 and 72 hours, cells were stained with Trypan blue stain (ThermoFisher, 0.4%) and counted 
using a hematocytometer. Each independent experiment was performed in technical duplicate. 
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In Vitro Tube Formation Assay 
In vitro tube formation assay was modified from a published protocol 138. Briefly, following 
transfections of indicated miRNA or siRNA, HLMVEC were seeded between 0.65 to 0.75 x 104 
cells per well in a 96-well plate, pre-coated with growth factor-reduced matrigel (Fisher 
Scientific). In order to visualize the structures formed, calcein AM (Fisher Scientific; 2µM, 15min) 
was added after 6 hours to each well and images were captured in a blinded fashion, using 
Nikon Eclipse Ti-U inverted microscope with Nikon Elements BR v4.30.02 software. Data were 
analyzed using Angiogenesis Analyzer in Image J. Each independent experiment was 
performed in technical triplicate. 
Electric Cell-substrate Impedance Sensing (ECIS) 
Cells were plated on the ECIS 8W10E chamber (Applied Biophysics, NY) with gold 
electrodes. The confluency of cell was measured as capacitance, using the ECIS machine 
(Applied Biophysics, NY) under high frequency alternating currents (64000Hz). miRNA 
transfections or AC/CS exposures were only conducted when the capacitance was < 10, which 
indicates the formation of a confluent monolayer. Recording was started 15 – 30 minutes before 
AC/CS exposure and resistance was measured under low frequency at 4000Hz, in real time for 
16 hours. Resistance measurements collected were all normalized to the initial resistance at the 
time treatment was started. 
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Caspase-3/7 Activity 
HLMVEC were cultured in an opaque 96-well plate with clear bottom and transfected as 
indicated. The caspase activity was measured using the Caspase-Glo-3/7 assay kit (Promega), 
following the manufacturer’s instructions.  
Western Blot 
Western blot was performed as previously described 139. Briefly, following treatments, 
cultured cells were washed on ice with cold PBS and gently detached with a cell scraper. Cell 
suspension was spun at 16,000 g for 10 minutes at 4 °C, the supernatant was discarded, and 
the pellets were lysed on ice in RIPA buffer (R0278, MilliporeSigma) supplemented with 
phosphatase inhibitor (Cat#04906837001, Roche Diagnostics) and protease inhibitor 
(Cat#04693116001, Roche Diagnostics). After 30 minutes, the cell lysate was sonicated and 
centrifuged at 16,000 g for 10 minutes at 4 °C, and the supernatant was used for assays. 
Protein concentration was determined by a bicinchoninic assay (BCA) (Pierce Biotechnology, 
Inc.,Rockford, IL) using bovine serum albumin (BSA) as a standard. Western blots were 
performed by loading equal amount of protein (10-50 μg) resolved by SDS-PAGE and 
transferred onto a PVDF membrane (EMD Millipore). Membranes were blocked with either 5% 
BSA in Tris-buffered saline, 0.1% Tween 20 (TBS-T) or Protein-Free T20 blocking buffer 
(Thermo Fisher Scientific Inc.) and incubated with diluted primary antibodies at 4°C overnight 
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per manufacturers’ specifications. All antibodies used are listed in Table II-3. 
Gene Expression Studies 
Total RNA (including miRNA and mRNA) was isolated using the miRNeasy mini kit 
(Qiagen, Germantown, MD), following the manufacturer’s instructions. Real-time quantitative 
polymerase chain reaction (qPCR) was performed on the StepOnePlus System using Taqman 
Universal PCR Master Mix (ThermoFisher) and Taqman gene expression assays. For microRNA 
studies, RNU48 was used as reference gene. For mRNA studies, 18S was used as reference 
gene. All primers are listed in Table II-4. 
miR-126 Standard Curve and Copy Number Calculation  
Synthetic miR-126-3p or miR-126-5p mimics (Dharmacon) were diluted at 5 x 10-1, 5 x 
10-2, 5x 10-3, 5 x 10-4, 5 x 10-5 ng and RT-qPCR was performed using Taqman miR-126-3p or -
5p expression assay. The value of qPCR cycle threshold (Ct) of each dilution gradient was 
plotted with corresponding RNA concentration (log10 transformed) to generate a standard curve 
from which the amount (ng) of miR-126 can be calculated based on the Ct value of an unknown 
sample. To minimize the impact of loading variations, Ct of miR-126 was adjusted based on the 
Ct of reference gene U48. Using the amount of miR-126 derived from the standard curve, the 
copy number of miR-126 in each sample was calculated as follows: copy number = (ng of RNA 
x 6.022 x 1023)/(length of ssRNA x 109 x 340); The mature sequence of miR-126-3p is 22nt 
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(UCGUACCGUGAGUAAUAAUGCG) and miR-126-5p is 21nt 
(CAUUAUUACUUUUGGUACGCG).  
RNA Sequencing 
HLMVEC from three individual donors (ID: 0000612039, 0000489936, 0000525116) 
purchased from LONZA were transfected with miR-126-3p mimics or inhibitors (5nM each, 
16hrs). For controls, cells co-transfected with non-targeting mimics and antisense inhibitors 
(5nM each, 16hrs) were used. Total RNA was isolated using the miRNeasy mini kit (Qiagen, 
Germantown, MD), following the manufacturer’s instructions. The isolated total RNA was 
processed for next-generation sequencing (NGS) library construction as developed in the NJH 
Genomics Facility for analysis with an Illumina 2500 (San Diego, CA, USA). A Kapa Biosystems 
(Wilmington, MA, USA) KAPA mRNA HyperPrep kit for whole transcriptome libraries was used 
to primarily target all polyA RNA. Briefly, library construction started from isolation of total RNA 
species, followed by mRNA (poly-A) isolation, 1st and 2nd strand cDNA synthesis, adaptor 
ligation, amplification, and cluster generation. Once validated, the libraries were sequenced as 
barcoded-pooled samples and ran on the HiSeq 2500. Illumina TruSeq adapters were removed 
from RNA-seq reads with skewer (version 0.2.2) 140. After adapter removal, reads with length 
less than 18 were removed (default setting for skewer). The quality of the reads was assessed 
using FastQC141 (version 0.11.5) before and after read trimming. Reads were mapped with the 
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STAR aligner (version 2.5.1b) 142 to the hg19 assembly of the human genome using gene 
annotations from Ensembl version 75143. Reads mapping to each gene of the Ensembl 75 
annotation were counted with the featureCounts program from the Subread software package 
(version 1.6.2) 144. The counts were transformed using the variance-stabilizing transform (VST) 
in DESeq2 145 version 1.20.0. Before comparing expression between groups, genes with 
expression <1 count per million (CPM) in at least three samples were removed. Statistical 
modeling was performed using a linear mixed effect model with the lme4 package (version 
1.1)146 for the R statistical software (version 3.6). Hypothesis testing of the regression 
coefficients was performed using the contest function in the lmerTest package (version 3.1)147. 
The p-values reported were adjusted for multiple testing using the method by Benjamini & 
Hochberg148. 
All raw data files can be downloaded from the gene expression ombinus, GEO: 
GSE141129.  
Linear Mixed-Effect Model for Regression  
Although the RNA-seq data did not accurately measure the amount of miR-126 in each 
sample, qPCR estimates of the miRNA counts were calculated through RT-qPCR as described 
earlier (copy numbers listed in Table IV-1). This quantitative information was used for a 
regression analysis. A linear mixed effects model was used to explain the expression of each 
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gene. The dependent variable, the VST of the counts, was modeled as a function of miR-126 
amount (specifically, the log2-transformed miR-126 copy numbers) and the sample donor. The 
miR-126 copy number variable was treated as a fixed effect in the regression, along with a fixed 
y-intercept, while the donor was treated as a random effect. Intuitively, this fits a line to the gene 
expression as a function of the miR-126 amount, with an offset (shifting the line up or down) 
specific to each individual donor. The model terms were fit using restricted maximum likelihood 
(REML) estimation. The model’s fit converged for 13, 360 of the 14, 517 tested genes. The 
remaining genes went unmodeled and were not included in the hypothesis testing. The 
regression slope and y-intercept for each gene’s regression were extracted from the model. 
Intuitively, the slope can be interpreted as the predicted change in VST of the counts for a 
particular gene when the quantity of miR-126 is doubled (it should be noted that the VST itself 
acts as a log-transformation of the counts in most circumstances). Genes with positive 
coefficients were positively correlated with miR-126, and genes with negative coefficients were 
negatively correlated with miR-126. The significance of the slope term in the model was 
obtained using a t-test, under the null hypothesis that the slope was zero. The p-values were 
adjusted for multiple testing. 
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Ingenuity Pathway Analysis (IPA) 
Following RNA sequencing, genes significantly correlated with miR-126 levels (co-
efficient ¹ 0, adjusted-p value <0.05) were uploaded and analyzed using the Ingenuity Pathway 
Analysis software (IPA, QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) to investigate 
signaling pathways regulated by miR-126. A core canonical signaling pathway analysis was 
performed and the Z-scores and p-values were calculated by the IPA using Fisher’s Exact Test. 
Pathways with p-value less than 0.05 were visualized and ranked by z-scores.  
Ambient Air Control (AC) and CS Extract Preparation and Exposure 
CS extract was prepared by bubbling the smoke from two cigarettes (3R4F, University of 
Kentucky, Lexington, KY), burnt at 1 min/ cigarette, and AC extract was prepared by bubbling 
room air for 2 min, each into 20 mL of PBS (100% v/v). AC and CS extracts were then adjusted 
to pH=7.4 and filtered with 0.22-µm filters as previously described 149. HLMVEC were incubated 
with extracts (1% or 3% v/v; 6 hrs) in EGM-2 MV starvation media containing 2% FBS and 
growth factors (40% of concentrations used for full culture media).  
Quantifications and Statistical Analysis 
All data were presented as means ± standard error of the mean (SEM). Between 3-6 
individual experiments were performed for each endpoint, which may affect the power of 
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statistical tests due to small sample size. Statistical analyses were performed with Prism v7.0 
software (GraphPad Software, La Jolla, CA) using Friedman non-parametric test followed by 
Dunn’s multiple comparisons test, one-way analysis of variance (ANOVA), or Two-way ANOVA 
as indicated. P < 0.05 was considered statistically significant. To note, Dunnett’s multiple 
comparisons test was used when comparing the mean of each experimental group to the 
control group, and Tukey’s post-hoc multiple comparisons test was used when comparing the 
means of all groups, regardless of control. Specific test used in each experiment is specified in 
the corresponding figure legend. Normality and variance were not tested to determine whether 
the applied parametric tests were appropriate. 
Rigor and Reproducibility 
Donor information (sex and age) of HLMVEC were masked during the performance and 
analyses of experiments to ensure unbiased measurements. Therefore, it is notable that age 
and sex were not matched or taken into account for result interpretations in this thesis. Only 
cells between passage 3-7 were used to ensure maintenance of endothelial phenotypes. To 
ascertain that our findings were universal to all HLMVEC instead of being specific to cells from a 
certain individual, all experiments were repeated with HLMVEC from at least three individual 
donors. Detailed donor information as well as the usage of HLMVEC from each individual donor 
were included in Table II-5. In addition, cell counting in all immunofluorescence studies were 
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performed blinded to eliminate bias. Outliers were defined as values beyond twice the standard 
deviation from the mean. However, since variations in our studies could be due to biological 
differences between individual donors, we did not omit any values in our studies.   
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Table II- 1. Reagents 
Name Vendor  Catalog # 
JPH203 Selleckchem S8667 
Rapamycin Sigma R0395-1MG 
Caspase-Glo 3/7 Assay 
System 
Promega PRG8090 
TaqMan Universal PCR 
Master Mix 
ThermoFisher 4364338 
 
ProLong Gold Antifade 
Mountant  
ThermoFisher 
 
P36931 
 
Calcein AM Fluorescent Dye Fisher Scientific 08-774-500 
Lipofectamine RNAiMax 
Transfection Reagent 
ThermoFisher 
 
13778150 
 
Matrigel GFR Membrane 
Matrix  
Fisher Scientific 
 
CB-40230A 
 
 
Table II- 2. miRNAs and siRNAs 
Name Vendor  Catalog # 
MicroRNA Hairpin Inhibitor 
Transfection Control with 
Dy547 
Dharmacon 
 
IP-004500-01-05 
 
MiRIDIAN microRNA Mimic 
Transfection Control with 
Dy547 
Dharmacon 
 
CP-004500-01-05 
 
MiRIDIAN microRNA Mimics 
for hsa-mir-126-3p 
Dharmacon 
 
C-300626-07-0002 
 
MiRIDIAN microRNA Hairpin 
Inhibitors for hsa-mir-126-3p 
Dharmacon 
 
IH-300626-08-0002 
 
ON-TARGETplus Non-
targeting Pool 
Dharmacon 
 
D-001810-10-05 
 
Accell SLC7A5 siRNA Dharmacon E-004953-00-0005 
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Table II- 3. Antibodies 
Target antigen Vendor or Source Catalog # Working 
concentration 
Human LAT1/SLC7A5 Cell Signaling Technology 5347S 0.026µg/ml 
Human ADAM9 Cell Signaling Technology 4151S 0.026ug/ml 
Phospho-ribosomal 
protein S6 (Ser235/236) 
Cell Signaling Technology 2211S 0.0189µg/ml 
Ribosomal protein S6 Cell Signaling Technology 2217S 0.037µg/ml 
Phospho-p70 S6 kinase 
(Thr389) 
Cell Signaling Technology 9205S 
 
0.03µg/ml 
P70 S6 kinase Santa Cruz sc-8418 0.4µg/ml 
Atg 7 Cell Signaling Technology 8558S 0.04µg/ml 
Atg 5 Cell Signaling Technology 12994S 0.3µg/ml 
Cleaved- PARP Abcam ab32064 0.5µg/ml 
SQSTM1 (p62) Abnova H00008878-
M01 
0.1µg/ml 
Ki67 Santa Cruz sc-23900 
AF488 
1µg/ml 
b-actin Sigma A5441 1:6000 
Vinculin Abcam ab18058 0.33µg/ml 
GAPDH Abcam ab9485 0.33µg/ml 
Anti-rabbit IgG HRP Fisher Scientific 45-000-683 1:10000 
Anti-mouse IgG HRP Fisher Scientific 45-000-679 1:10000 
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Table II- 4. Quantitative real-time PCR primers 
Name Vendor or Source Catalog # 
Taqman gene expression assay: 
SLC7A5 
ThermoFisher Hs01001189_m1 
Taqman gene expression assay: 
ITGA6 
ThermoFisher Hs01041011_m1 
Taqman gene expression assay: 
PTPN9 
ThermoFisher Hs00361739_m1 
Taqman gene expression assay: AKT2 ThermoFisher Hs01086099_m1 
Taqman gene expression assay: 
ADAM9 
ThermoFisher Hs00177638_m1 
Taqman gene expression assay: 
CAMSAP1 
ThermoFisher Hs00251465_m1 
Taqman gene expression assay: BAK1 ThermoFisher Hs00832876_g1 
Taqman gene expression assay: 
LARP6 
ThermoFisher Hs00217969_m1 
Taqman gene expression assay: CRK ThermoFisher Hs00180418_m1 
Taqman gene expression assay: DLK1 ThermoFisher Hs00171584_m1 
 
Taqman gene expression assay: 
SERPINE1 
ThermoFisher Hs00167155_m1 
 
Taqman gene expression assay: 18s ThermoFisher Hs99999901_s1 
Taqman microRNA expression assay: 
hsa-miR-126-3p 
ThermoFisher 4427975 (assay ID: 002228) 
Taqman microRNA expression assay: 
hsa-miR-126-5p 
ThermoFisher 4427975 (assay ID: 000451) 
Taqman microRNA control assay: 
RNU48 
ThermoFisher 4427975 (assay ID: 001006) 
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Table II- 5. Lonza human lung microvascular endothelial cells (HLMVEC) 
 
 
  
Cat #: CC-2527 
Donor ID (Lot #) Sex Age Usage 
0000612039 Female 63 RNA-seq, Western blot analysis of 
apoptosis 
0000525116 Female 52 RNA-seq, Western blot analysis of 
apoptosis and mTOR activity, 
proliferation, tube formation, caspase 
activity, growth curve 
0000489936 Female 2 RNA-seq, Western blot analysis of 
apoptosis, proliferation, tube formation, 
caspase activity 
0000549135 Female 55 Western blot analysis of mTOR activity, 
tube formation, caspase activity 
0000421710 Female 69 Proliferation, Western blot analysis of 
apoptosis  
0000441097 Female 46 Tube formation, caspase activity 
0000547317 Male 57 Tube formation, proliferation  
18TL204558 Male 40 Tube formation, Western blot analysis 
of mTOR activity, apoptosis, and growth 
curve 
18TL012117 Male 44 Proliferation, Western blot analysis of 
mTOR activity  
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Chapter III 
FUNCTION OF MICRORNA-126 IN HUMAN LUNG MICROVASCULAR ENDOTHELIAL 
CELLS3 
Introduction 
Highly enriched in the endothelial cells, microRNA-126-3p (herein referred to as miR-
126) is essential for vascular development by maintaining vascular integrity and promoting 
angiogenesis27, 35, a highly regulated process involving cell proliferation, invasion, and 
migration20. A similar effect of miR-126 has been shown in cultured endothelial cells such as 
HUVEC27, 35, HAEC27, and HCAEC47. However, the role of miR-126 in regulating the angiogenic 
function of microvascular endothelial cells has not been elucidated. The majority of miR-126 
studies in endothelial cells were performed based on the assumption that the function of miR-
126 in one endothelial cell type will apply in others, despite the fact that endothelial cells are 
highly heterogeneous, possessing distinct transcriptional and functional profiles influenced by 
the stage of organismal development, type of vascular bed, tissue or organ of origin, and 
pathogenic states 46, 72, 150. For example, an anti-angiogenic and anti-proliferative effect of miR-
126 have been reported in late EPC 29, in hematopoietic stem cell 31, and in pathological 
proliferative microvascular states such as choroidal neovascularization 49, diabetic retinopathy 
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 Portions of this chapter were previously published in Arteriosclerosis, Thrombosis, and 
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48, or various cancers 30, 53, 151, indicating that miR-126 function is likely cell-type and/or disease-
specific.  
Serving as a critical component of the alveolar-capillary membrane85, 152, the lung 
microvascular endothelial cells not only form a tight barrier and facilitate gas exchange, but also 
play an important role in regulating lung homeostasis. The pro-angiogenic function of lung 
microvascular cells may also be required for the prevention and repair of lung injury in response 
to environmental insults, such as CS, which is the major risk factor for COPD, a chronic lung 
disease featuring extensive lung vascular cell death and destruction. We therefore set out to 
determine the role of miR-126 in lung microvascular endothelial cells during homeostasis and 
CS exposure.  
Objectives 
• Determine the effects of miR-126 on primary HLMVEC angiogenic function including 
proliferation and tube formation and survival during homeostasis 
• Determine the effects of miR-126 on HLMVEC angiogenic function and survival during 
CS exposure 
• Determine the effect of miR-126 on HLMVEC barrier function 
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Results 
miR-126 inhibits cell proliferation and tube formation and triggers apoptosis in HLMVEC 
To study the effect of miR-126 on HLMVEC proliferation, we transfected primary 
HLMVEC with miR-126 mimics (5nM, 16hrs) for miR-126 overexpression (126-OE), antisense 
miR-126 inhibitors (5nM, 16hrs) for miR-126 knockdown (126-KD), or co-transfected non-
targeting mimics and inhibitors (5nM each, 16hrs) as negative control (Chapter II, Fig II-1). After 
16 hours, the transfected cells were re-plated at equal number and the expression of Ki67, a 
nuclear protein strictly expressed only in proliferating cells153, was measured using 
immunofluorescence 24 hours later. Compared to control cells, 126-OE significantly decreased 
whereas 126-KD increased the percentage of Ki67 positive cells (Fig III-1A), suggesting that 
miR-126 negatively regulates HLMVEC proliferation.  
We next investigated the effect of miR-126 on the angiogenic function of HLMVEC by 
performing tube formation assays, which access the coordinated function of endothelial cell 
adhesion, migration, and formation of capillary-like structure in vitro138. Following the same 
transfection strategy, we seeded HLMVEC in matrigel and observed branching and formation of 
tube/mesh-like structures as early as 4 hours (data not shown), with a peak between 6 to 8 
hours. At 6 hours, 126-OE markedly decreased the number of meshes formed by more than 
50% and total branching length by 15%. Although there was no significant difference in the 
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numbers of meshes formed between control and 126-KD conditions, 126-KD increased the total 
branching length by more than 20% relative to control (Fig III-1B). 
Since angiogenesis can be affected by endothelial cell survival154, we next determined 
the effect of miR-126 on HLMVEC apoptosis by assessing the levels of cleaved-poly (ADP-
ribose) polymerase (cleaved-PARP) using Western blot and caspase 3/7 activity using a 
luminescence activity assay. Compared to the control cells, we detected significantly higher 
levels of cleaved-PARP (Fig III-1C) and active caspase 3/7(Fig III-2D) in 126-OE HLMVEC. 
Although we did not observe any difference in caspase 3/7 activity between control and 126-KD 
cells (Fig III-1D), 126-KD significantly reduced the cleaved-PARP levels by almost 50% relative 
to control (Fig III-1C). 
Changes in miR-126 expression may lead to feedback regulation of its sister strand miR-
126-5p, which can independently regulate endothelial proliferation and angiogenesis33, 49. We 
therefore measured the expressions of miR-126-5p and its primary targets DLK1 and 
SERPINE1 by RT-qPCR and found that miR-126-5p was expressed at only 25% of the 
abundance of miR-126-3p and the up- and down-regulations of miR-126 we performed through 
transfection did not affect miR-126-5p, DLK1, and SERPINE1 expressions (Fig III-2). Therefore, 
the inhibitory effects we observed on proliferation, tube formation, and cell survival were specific 
to miR-126 and together, our findings suggest that miR-126 plays an anti-angiogenic and pro-
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apoptotic role in HLMVEC.  
126-KD ameliorates the pro-apoptotic and anti-angiogenic effects of CS exposure 
We and others have previously reported that CS exposure induces apoptosis and 
impairs angiogenesis of the lung microvasculature 155, 156. We next determined whether the 
newly discovered function of miR-126 in HLMVEC can be employed to modulate their response 
to injury induced by CS exposure. HLMVEC transfected with negative controls, miR-126 mimics, 
or miR-126 antisense inhibitors (5nM respectively, 16hrs) were seeded on matrigel and 
incubated with media containing aqueous CS or AC extracts (1% v/v, 6hrs). After 6 hours, we 
found that relative to AC, the mesh number and total branching length of HLMVEC exposed to 
CS were significantly reduced (Fig III-3A). Compared to CS-exposed control cells, the total 
branching length was further reduced by 126-OE, and was improved by 126-KD, the latter also 
tended to increase mesh number (Fig III-3A). In addition, CS exposure (3% v/v, 6 hrs) increased 
the levels of cleaved-PARP and caspase 3/7 activity in HLMVEC, as expected (Fig III-3B-C). 
Among CS-exposed cells, 126-OE did not further increase levels of cleaved-PARP and caspase 
3/7 activity, whereas 126-KD significantly reduced the levels of both markers, strikingly by more 
than 50% (Fig III-3B-C). These results suggest that miR-126 knockdown improves HLMVEC 
angiogenic functions and reduces cell death during CS exposure.  
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126-KD improves endothelial cell barrier function during CS exposure 
To determine the effects of miR-126 on endothelial cell barrier function, we utilized the 
ECIS technique which applies a small alternating current to cell monolayer and measures the 
current impedance. At relatively low current frequency (2000~4000Hz), the electric currents 
generally flow between and under adjacent cells, and therefore the impedance encountered by 
the currents are suggestive of the strength of intercellular barrier157. We transfected confluent 
HLMVEC monolayer grown on ECIS array chambers with non-targeting controls, miR-126 
mimics, or miR-126 antisense inhibitors (5nM, 16hrs) and exposed these transfected cells to AC 
or CS extract (2% v/v) for 24 hours. The current impedance was measured real-time by ECIS as 
resistance during transfection and throughout the AC/CS exposure. We observed no change in 
resistance during AC exposure between control, 126-OE, and 126-KD conditions, indicating that 
miR-126 may not affect HLMVEC barrier at baseline (Fig III-4). During CS exposure, the CS-
induced barrier disruption was attenuated in 126-KD condition (Fig III-4B), whereas no effect 
was seen in 126-OE condition compared to control (Fig III-4A). 
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Figure III- 1. Effect of miR-126 on human lung microvascular endothelial cell (HLMVEC) 
proliferation, tube formation, and apoptosis.  
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Figure III-1. Effect of miR-126 on human lung microvascular endothelial cell (HLMVEC) 
proliferation, tube formation, and apoptosis.  
A, Left: Immunofluorescence (IF) images of HLMVEC stained for Ki67 (green) and DAPI (blue), 
24hrs after transfection with a mixture of miRNA non-targeting mimics and inhibitor controls 
(Ctrl), miR-126 mimics (126-OE) or miR-126 antisense inhibitors (126-KD). Scale bar: 50µm. 
Right: Quantification of Ki67 expression by first normalizing the number of Ki67 positive cells to 
the total number of cells (DAPI) and then to the Ctrl condition. At least 10 images were analyzed 
per individual experiment. B, Top: Images of mesh-like structures formed by HLMVEC in 
matrigel 6hrs after seeding; cells were stained with calcein AM (Green). Scale bar: 200µm. 
Bottom: Quantifications of total mesh number (left) and total branching length (right) analyzed 
by the Angiogenesis Analyzer in Fuji. Each experiment was performed in technical triplicate. C-
D, Cell apoptosis measured by cleaved-PARP level using Western Blot (C) and by caspase 3/7 
activity measured using a Promega luminescence assay (D). Results presented as mean ± 
SEM; *p<0.05; **p<0.01; One-way ANOVA followed by Dunnett’s multiple comparisons test. 
Each data point represents an individual experiment; At least three induvial donors were used 
per assay to eliminate the contribution of donor-specific effects. 
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Figure III- 2. Effects of miR-126 (3p) manipulation on the expressions of miR-126-3p, mir-
126-5p, and primary miR-126-5p targets.  
A. Relative miR-126 copy numbers calculated following: copy number = (ng of RNA x 6.022 x 
1023)/(length of ssRNA x 109 x 340); amount (ng) of miR-126 in each sample was calculated 
from a standard curve derived from qPCR using gradient-diluted miR-126-3p or miR-126-5p 
mimics; the length of mature miR-126-3p is 22nt (UCGUACCGUGAGUAAUAAUGCG) and the 
length of mature miR-126-5p is 21nt (CAUUAUUACUUUUGGUACGCG). Mean of each 
experimental group is indicated. B. Expression levels of miR-126-5p targets, DLK1 and 
SERPINE1, determined by RT-qPCR. *p<0.05; **p<0.01; One-way ANOVA followed by 
Dunnett’s multiple comparisons test. Each data point represents an individual experiment; At 
least three induvial donors were used per assay to eliminate the contribution of donor-specific 
effects. 
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Figure III- 3. Effects of miR-126 on cigarette smoke (CS)-exposed HLMVEC.  
A. Top: tube formation by HLMVEC seeded in matrigel with 1% (v/v) ambient air (AC) or CS 
extract for 6hrs and stained with calcein AM (2µM, 15 min). Bottom: mesh number (left) and total 
branching length (right) analyzed by Angiogenesis Analyzer in Fuji. Each experiment was 
performed in technical triplicate. Scale bar: 200µm. B-C. Cell apoptosis measured by cleaved-
PARP levels (left and middle, B) and caspase 3/7 activity (right, C) after treating the cells with 
AC or CS extract (3% v/v, 6hrs). Results presented as mean ± SEM; *<0.05; **p<0.01; One-way 
ANOVA followed by Tukey’s post-hoc multiple comparisons. Each data point represents an 
individual experiment; At least three induvial donors were used per assay to eliminate the 
contribution of donor-specific effects. 
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Figure III- 4. Effect of miR-126 on HLMVEC barrier in response to CS exposure.  
A-B. Changes in endothelial barrier in 126-OE HLMVEC (A) or 126-KD HLMVEC (B) compared 
to cells transfected with non-targeting control during AC or CS extract exposure (1%, v/v, 16hrs). 
Endothelial barrier was measured as current resistance using Electric Cell Impedance Sensing 
(ECIS) and all measurements were normalized to the resistance at the time when AC and CS 
extract were added to cell culture (0h). One-way ANOVA followed by Tukey’s post-hoc multiple 
comparisons was performed. Results presented as mean ± SEM; *<0.05; **p<0.01; Statistical 
significance was only detected between CS+Ctrl and CS+126-KD conditions in B. Each data 
point represents an individual experiment; At least three induvial donors were used per assay to 
eliminate the contribution of donor-specific effects. 
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Discussion 
By performing overexpression and knockdown of miR-126 in HLMVEC, we 
demonstrated that miR-126 is a negative regulator of HLMVEC proliferation and angiogenesis. 
We found that high levels of miR-126 induce baseline apoptosis whereas low levels of miR-126 
decreases apoptosis.  
When analyzed in light of previous studies reporting a pro-angiogenic role of miR-126 27, 
35, 44, we interpreted our results as an indication of the intrinsic diversity of the endothelial cells 
from the macro- and micro-vasculature beds, and the distinct developmental stage of the 
vasculature 46, 72, 150. Indeed, similar to our findings in HLMVEC, an anti-angiogenic function of 
miR-126 was reported in human late EPC 29, which are highly proliferative and angiogenic 158. 
HLMVEC share these attributes, relative to other lung endothelial cell types such as the 
pulmonary artery endothelial cells 159. Additionally, high miR-126 levels drive hematopoietic stem 
cell towards quiescence state by limiting cell proliferation31. The anti-angiogenic effects of miR-
126 have also been reported in pathological conditions that result from hyperproliferative 
microvasculature beds including choroidal neovascularization 49, diabetic retinopathy 48, and 
various forms of cancer 53, 151, 160. All these conditions feature excessive angiogenesis with high 
endothelial proliferative rate and excessive vascular branching which can be inhibited by the 
overexpression of miR-12648, 53. These results, together with our current study, suggest that the 
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function of miR-126 is endothelial cell type-specific and in cells with high proliferative potentials, 
miR-126 may be kept at high level to prevent unwanted proliferation or angiogenesis, which can 
lead to cancer and diseases.  
Although it has been shown that miR-126-5p also participates in the regulation of 
endothelial cell proliferation49, we are confident that the functional effects described here were 
specific to miR-126-3p since no significant change was detected in miR-126-5p or its principal 
targets DLK1 and SERPINE1. 
Our data demonstrated that miR-126 did not regulate endothelial barrier function at 
baseline but was able to ameliorate barrier disruption caused by CS exposure. Since we also 
found that 126-KD reduces CS-induced apoptosis, it remains unclear whether the beneficial 
effect of 126-KD on endothelial barrier during CS exposure is primarily due to reduced cell 
death or stronger cell-cell junctions. Apoptosis inhibitor should be used in the future to address 
this question and the expression of proteins that are important for endothelial junction (i.e VE-
Cadherin and ZO-1/2161) should be determined during miR-126 manipulations.   
At last, we were able to leverage the pro-angiogenic and anti-apoptotic effects of 
decreased miR-126 to protect HLMVEC from environmental insults such as CS exposure. Our 
findings that 126-KD alleviated CS-induced cell death and enhanced angiogenesis and 
endothelial barrier may inform the design of interventions promoting the survival and fitness of 
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these cells under disease conditions. Chronic CS exposure causes extensive lung endothelial 
cell death which contributes to the pathogenesis of emphysema, a phenotype of COPD 
characterized by net loss of alveolar gas exchange area 90. It remains unclear if miRNA-126 
plays a role in the development of CS-induced emphysema. We have previously reported that 
acute exposure to CS increases the release of miR-126 within exosomes and decreases the 
intracellular miR-126 levels in HLMVEC 162. In light of our data, the decrease in intracellular 
miR-126 is likely an adaptive response. Although HLMVEC have high proliferative potential and 
may possess progenitor property84, during homeostasis they remain mostly quiescent and rarely 
proliferate20. In response to CS exposure, miR-126 may be downregulated to promote cell 
proliferation, which is supported by previous reports showing that short-term CS exposure 
activates pro-survival signaling such as AKT and mTOR 163, 164.  
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Chapter IV 
TRANSCRIPTOME AND SIGNALING PATHWAYS REGULATED BY MICRORNA-126 IN 
LUNG MICROVASCULAR ENDOTHELIAL CELLS4 
Introduction 
In Chapter III, we demonstrated that distinct from the pro-angiogenic role reported in 
endothelial cells from larger vessels such as HUVEC and HAEC, miR-126 plays an inhibitory 
role in HLMVEC, suppressing cell proliferation and angiogenesis. The functions of miRNAs are 
carried out through post-transcriptional inhibition, which is mediated by the interaction between 
the “seed sequence” of a miRNA and the 3’-UTRs of its mRNA targets 1, 12. This interaction can 
be predicted using computational algorithms available through databases such as miRDB 15, 165 
and TargetScan 13. A single miRNA can target multiple mRNAs at the same time and the 
preferred targets of a miRNA can vary significantly between cell types partially as a result of 
differential target gene abundance1, 12. Given the remarkable heterogeneity within endothelial 
cells46, we hypothesize that distinct effect of miR-126 in HLMVEC is due to inhibition of a unique 
set of target mRNAs.  
The mechanism underlying the pro-angiogenic function of miR-126 involves direct 
inhibition of SPRED1 and PIK3R2, with subsequent disinhibition of the VEGF and FGF signaling 
 
4 Portions of this chapter were previously published in Arteriosclerosis, Thrombosis, and 
Vascular Biology and are included with the permission of the copyright holder. 
Citation: Cao D et al., Arterioscler Thromb Vasc Biol. 2020;40:1195-1206  
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pathways 27, 35, 47. On the contrary, the anti-angiogenic effects of miR-126 reported in highly 
proliferative cell types including EPC, hematopoietic stem cells and varies cancer cells were 
primarily mediated through a distinct set of targets including VEGF-A 49, 160, PIK3R2 31, 53, 
ADMA9 56, and SLC7A5 60, 166, suggesting that the functions and targets of miR-126 may be cell 
type- and disease-specific. Since the target of miR-126 in HLMVEC has not been studied, we 
aimed to identify mRNAs directly regulated by miR-126 in HLMVEC using global gene 
sequencing followed by bioinformatic target prediction. We also performed pathway analysis on 
data obtained from gene sequencing to gain insights on overall cellular functions and signaling 
pathways affected by miR-126.  
Objectives 
• Determine genes that are significantly associated with miR-126 levels in HLMVEC 
• Determine direct targets of miR-126 in HLMVEC 
• Determine signaling pathways regulated by miR-126 in HLMVEC, particularly mTOR and 
VEGF signaling pathways 
Results 
Global transcriptome and signaling pathways regulated by miR-126 in HLMVEC 
To identify genes regulated by miR-126 in HLMVEC and to subsequently determine 
direct gene targets of miR-126 in these cells, we transfected HLMVEC from three individual 
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donors with non-targeting controls, miR-126 mimics, or miR-126 antisense inhibitors at 5nM 
each for 16 hours. We next calculated the copy number concentration of miR-126 in each 
sample using a PCR standard curve (Table IV-1, calculation details see Methods) and 
performed genome-wide RNA sequencing (RNA-seq) on these samples. In order to identify 
genes whose expressions were the most significantly affected by miR-126 levels, we plotted the 
gene expression data from RNA-seq for each transfection condition (Ctrl, 126-OE and 126-KD) 
against their respective miR-126 copy numbers and performed a linear regression analysis (Fig 
IV-1A). We found that 1258 genes were positively correlated, and 1425 genes were inversely 
correlated with miR-126 levels (Fig IV 1B). Notably, we did not observe significant correlations 
between miR-126 and SPRED1, PIK3R2, or VEGFA (Fig IV 1B, labelled in grey), suggesting 
that these genes related to VEGF signaling53, 160 may not be primary targets of miR-126 in 
HLMVEC. To interpret our gene expression results in the perspective of cellular processes and 
signaling pathways, we performed the QIAGEN Ingenuity Pathway Analysis (IPA) on our data 
and noted that high levels of miR-126 promoted an anti-angiogenic and pro-apoptotic profile 
(Table IV-2), featuring negative association with pathways involved in growth factor signaling 
(FGF, VEGF, hepatocyte growth factor (HGF), and angiopoietin), cell growth (p70S6K and eIF4), 
and cell motility (RhoA, actin cytoskeleton, and ephrin receptor signaling). In contrast, miR-126 
was positively associated with activation of pathways related to cell cycle arrest (p53 and PTEN 
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signaling) and apoptosis (TNFR1 and ceramide signaling). These results suggest that miR-126 
promotes a quiescent-like state in HLMVEC, which lacks signals that promote cell growth and 
angiogenesis and may even induce apoptosis.  
miR-126 regulates mTOR but not VEGF signaling in HLMVEC 
Results from our IPA analysis suggested an upregulation mTOR signaling and a 
potential inhibition of growth factor signaling, both are pathways essential for endothelial cell 
function and survival. However, since pathway analyses are performed based on gene 
expression profiles while activation of signaling pathways is generally carried out through 
protein modifications such as phosphorylation, we next sought to confirm the effects of miR-126 
on mTOR and growth factor signaling pathways, particularly VEGF, by assessing the 
phosphorylation status of the key effectors of these two pathways. Using Western blot, we 
measured the phosphorylation levels of mTOR effectors, S6K and S6, as well as the 
phosphorylation levels of VEGFR2 effectors, ERK and AKT, in control, 126-OE, and 126-KD 
HLMVEC. We noted that the 126-OE cells showed remarkably decreased whereas the 126-KD 
cells showed significantly increased S6K and S6 phosphorylation (Fig IV-2A). In the presence of 
rapamycin, 126-KD cells failed to increase S6 phosphorylation compared to cells treated with 
vehicle (Fig IV-2B), suggesting that mTOR is required for miR-126-mediated S6 activation. To 
discern the effect of miR-126 on VEGF signaling pathway, following transfection, we starved the 
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cells for 2 hours with serum-free, growth factor-free medium (basal medium) and re-activated 
the cells with basal medium containing only VEGF (50ng/mL, 10min). Compared to the 
starvation control, VEGF significantly increased phosphorylation of both ERK and AKT as 
expected (Fig IV-2C). However, we did not find any notable difference in the phosphorylation 
levels of ERK and AKT in the VEGF-treated, 126-OE or 126-KD HLMVEC compared to the 
VEGF-treated control cells (Fig IV-2C ). Together, these results indicate that mir-126 inhibits 
mTOR but may not regulate the VEGF signaling pathway.  
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Figure IV- 1. Global RNA-sequencing (RNA-seq) profiling of genes regulated by miR-126.  
A. Schematic overview of the study; HLMVEC from three individual donors were used as 
biological replicates. B. Volcano plot of genes positively (red) or negatively (blue) associated 
with miR-126 in HLMVEC with adjusted p< 0.05. Genes with adjusted p value > 0.05 are 
labelled in grey. The top 15 genes with the highest regression coefficient are annotated, as well 
as SPRED1 and VEGFA, known direct targets of miR-126 in HUVEC and cancer cells, 
respectively. 
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Figure IV- 2. Effects of miR-126 on mTOR and VEGF-mediated ERK and AKT signaling 
pathways. 
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Figure IV-2. Effects of miR-126 on mTOR and VEGF-mediated ERK and AKT signaling 
pathways. 
A. Activity of mTOR pathway measured by the phosphorylation levels of S6K and S6. Left: 
representative Western blot images. Middle, right: phosphorylation levels of S6K and S6 
quantified by normalizing the density of phosphorylated S6K (p-S6K) and phosphorylated S6 (p-
S6) to total S6K and S6, respectively. B. Activity of mTOR signaling after treatment of 
rapamycin, an mTOR inhibitor (0.5nM or 1nM, 6hrs). Top: representative Western blot image. 
Bottom: quantification of S6 activity C. Activities of ERK and AKT in HLMVEC transfected as 
indicated and subjected to serum and growth factor deprivation in endothelial basal medium 
(EBM) for 2 hours followed by reactivation with VEGF-containing EBM (50ng/mL, 10min). Top: 
representative Western blot image. Bottom: densitometry of ERK and AKT activity by 
normalizing p-ERK to ERK and p-AKT to AKT. Results presented as mean ± SEM; *p<0.05; 
**p<0.01; One-way ANOVA followed by Dunnett’s multiple comparisons test in A and C. Two-
way ANOVA was performed for analyses in B. Each data point represents an individual 
experiment; At least three induvial donors were used per assay to eliminate the contribution of 
donor-specific effects. 
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Bioinformatics analysis identifies SLC7A5 and ADAM9 as miR-126 targets in HLMVEC 
Since miRNAs regulate their targets through post-transcriptional silencing, we focused 
on genes identified by our regression analysis to have significant inverse correlations with miR-
126 (correlation coefficient <0; adjusted p<0.05) in order to determine direct targets of miR-126 
in HLMVEC. We compared these genes with genes predicted by miRDB and TargetScan (Fig 
IV-1A) and found that of the 1425 negatively associated genes, SLC7A5, CRK, CAMSAP1, 
ADAM9, PTPN9, and ITGA6 were predicted as direct targets of miR-126 by both miRDB and 
TargetScan databases (Fig IV-3A), with SLC7A5 ranked as the top predicted target using 
Aggregate PCT 
16. In addition, genes previously reported to regulate endothelial function and cell 
death such as LARP6, AKT2 and BAK1 167-169, were identified as miR-126 targets by either 
miRDB or by TargetScan (Fig IV- 3A). We assessed the expression of these 9 genes in Ctrl, 
126-OE, or 126-KD HLMVEC using RT-qPCR and noted that all genes tended to decrease with 
126-OE and increase with 126-KD (Fig IV-3B). However, only the expression of SLC7A5 and 
ADAM9 were significantly downregulated in 126-OE HLMVEC, by nearly 50% and upregulated 
in 126-KD HLMVEC, by more than 2-fold for both genes. In addition, we found that the protein 
expression of SLC7A5 and ADAM9 were regulated by miR-126 in a similar fashion (Fig IV-3C-
D).  
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Figure IV- 3. Bioinformatics prediction and validations of miR-126 direct targets.  
A. Venn diagram of genes negatively associated with miR-126 identified in our RNA-seq 
analysis (left, orange), genes predicted as direct targets of miR-126 by miRDB (right, green) and 
by TargetScan (middle, blue). The overlapped genes are annotated and listed based on 
Aggregate PCT (highest to lowest) calculated by the computational algorithms of the two 
databases. B. RT-qPCR quantification of the six genes identified by all three approaches (center 
of the Venn graph in A) as well as additional three candidate genes (LARP6, AKT2 and BAK1) 
with angiogenic functions (n=5, each date point represents an individual experiment). C-D. 
Western blot quantification of SLC7A5 and ADAM9 protein abundance. Results presented as 
mean ± SEM; *p<0.05; Statistical significance was determined by Friedman non-parametric test 
followed by Dunn’s multiple comparisons test in B.  
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Discussion  
Using genome-wide RNA-seq followed by IPA analysis, our study is the first to 
characterize the transcriptomic profile regulated by miR-126 in HLMVEC. We found that miR-
126 influenced the expressions of a wide range of genes associated with inhibitions on cell 
growth, cell motility, and growth factor signaling. We also found that miR-126 promoted a pro-
apoptotic profile featuring genes involved in pathways related to cell cycle arrest and apoptosis. 
These results are highly consistent with our findings reported in Chapter III that miR-126 played 
an anti-angiogenic, pro-apoptotic role in HLMVEC and support our hypothesis that mir-126 
could exert different functions by engaging distinct cellular pathways. We confirmed that miR-
126 negatively regulated mTOR signaling while imposing no obvious effect of on VEGF-
mediated ERK and AKT activation, which was complemented by our finding in RNA-seq that the 
expression of SPRED1 and PIK3R2, two well-established targets that mediate the pro-
angiogenic effects of miR-126 in response to VEGF in HUVEC27, 35, were not significantly 
associated with miR-126 levels in HLMVEC.  
We found that the expressions of SLC7A5 and ADAM9, at both mRNA and protein 
levels, were negatively associated with the expression miR-126. Since other research groups 
have confirmed using luciferase assay that miR-126 can directly interact with the 3’ -UTR 
binding areas of these two genes and lead to subsequently gene silencing56, 60, our finding 
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indicate that SLC7A5 and ADAM9 are direct targets of miR-126 in HLMVEC. Based on the 
knowledge that SLC7A5 is a primary leucine/glutamine antiporter which critically maintains 
intracellular leucine level and thereby regulates mTOR activity61, 130, the prominent inhibitory 
effect of miR-126 on mTOR signaling may be mediated through the inhibition of SLC7A5, a 
hypothesis that will be addressed in Chapter V. ADAM9 is a metalloprotease that can exist in 
two forms; the transmembrane form plays an important role during cell adhesion and migration 
by interacting with extracellular matrix while the soluble form is well-known for its role in 
promoting growth factor signaling by cleaving and allowing the release of active growth factors 
such as EGF and FGF58, 59. Our finding showing that miR-126 inhibits both the transmembrane 
and soluble forms of ADAM9 suggests that miR-126 may inhibit growth factor signaling and 
migration of HLMVEC via ADAM9.  
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Table IV- 1. Copy numbers of miR-126 in HLMVEC used for RNA-seq  
 
 
 
 
 
Donor ID Ctrl 126-OE 126-KD 
0000612039 225423673 3243703876 89204553 
0000489936 374103155 6712173364 241181094 
0000525116 225423673 4306650709 71200703 
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Table IV- 2. Ingenuity pathway analysis of genes significantly associated with miR-126 
Ingenuity Canonical Pathways -log(p-value) z-score Genes regulated in the pathway 
Ephrin Receptor Signaling 4.25 -2.711 ABI1,AKT1,AKT2,ARPC1B,ARPC5,AXIN1,CREB3,CRK,EFNB1,GNB1,GNB4,ITGA3,ITGA5,LIM
K1,MAP2K1,MAPK1,NRAS,PAK2,RAP1A,RHOA,ROCK1,RRAS,SDCBP,SHC1,SOS1 
Endometrial Cancer Signaling 6.63 -2.138 AKT1,AKT2,AXIN1,CTNNA1,CTNNB1,GSK3B,ILK,MAP2K1,MAPK1,NRAS,PDPK1,PIK3R3,PTE
N,RAP1A,RRAS,SOS1 
Androgen Signaling 2.2 -2.121 CACNG8,CALM1 (includes 
others),GNB1,GNB4,GTF2A1,GTF2B,GTF2H1,KAT2B,MAPK1,POLR2B,POLR2E,PRKAR2A,PR
KCA,PRKCD,SHC1,TBP 
Phospholipase C Signaling 4.3 -2.041 ADCY6,CALM1 (includes 
others),CREB3,GNB1,GNB4,HDAC1,HDAC3,HDAC5,HDAC8,ITGA3,ITGA5,ITPR1,ITPR2,MAP2
K1,MAPK1,MEF2C,NRAS,PEBP1,PLCB1,PLCG2,PLD1,PLD2,PPP3CA,PPP3CB,PRKCA,PRKC
D,RAP1A,RHOA,RHOBTB1,RRAS,SHC1,SOS1 
G Beta Gamma Signaling 3.1 -2 AKT1,AKT2,CACNG8,EGFR,GNB1,GNB4,MAPK1,NRAS,PDPK1,PLCG2,PRKAR2A,PRKCA,PR
KCD,RAP1A,RRAS,SHC1,SOS1 
Hypoxia Signaling in the Cardiovascular 
System 
1.95 -2 AKT1,ARNT,CREB3,NQO1,PTEN,UBE2B,UBE2C,UBE2H,UBE2R2,UBE2W 
Neuregulin Signaling 6.86 -1.886 AKT1,AKT2,CDK5R1,CDKN1B,CRK,EGFR,ITGA3,ITGA5,MAP2K1,MAPK1,NRAS,PDPK1,PIK3
R3,PLCG2,PRKCA,PRKCD,PTEN,RAP1A,RRAS,SHC1,SOS1 
Actin Cytoskeleton Signaling 2.29 -1.877 ABI2,ARPC1B,ARPC5,CRK,CSK,DIAPH3,IQGAP3,ITGA3,ITGA5,LIMK1,MAP2K1,MAPK1,MSN,
NRAS,PAK2,PIK3R3,RAP1A,RHOA,ROCK1,RRAS,SHC1,SOS1,WASF1 
IL-3 Signaling 4.31 -1.807 AKT1,AKT2,CSF2RB,MAP2K1,MAPK1,NRAS,PIK3R3,PPP3CA,PPP3CB,PRKCA,PRKCD,RAP1
A,RRAS,SHC1,SOS1 
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Table IV- 2 Continued 
FGF Signaling 3.99 -1.807 AKT1,AKT2,CREB3,CRK,FRS2,HGF,ITPR1,MAP2K1,MAPK1,MAPK13,MAPK8,MET,PIK3R3,P
RKCA,SOS1 
IL-7 Signaling Pathway 3.79 -1.732 AKT1,AKT2,BAK1,CDC25A,CDKN1B,GSK3B,HGF,MAPK1,MAPK13,MET,PDPK1,PIK3R3,SHC
1,SOS1 
Gαi Signaling 1.49 -1.732 ADCY6,GABBR2,GNB1,GNB4,MAPK1,NRAS,PRKAR2A,RAP1A,RGS10,RGS4,RRAS,SHC1,S
OS1 
Antioxidant Action of Vitamin C 1.3 -1.667 CSF2RB,MAP2K4,MAPK1,MAPK13,MAPK8,PLCB1,PLCG2,PLD1,PLD2,SLC2A14,SLC2A3 
Huntington's Disease Signaling 5.43 -1.606 AKT1,AKT2,APAF1,ATP5F1B,CASP3,CDK5R1,CREB3,DCTN1,EGFR,GNB1,GNB4,GOSR2,GP
AA1,HDAC1,HDAC3,HDAC5,HDAC8,HSPA9,ITPR1,MAP2K4,MAPK1,MAPK8,PDPK1,PIK3R3,P
LCB1,POLR2B,POLR2E,PRKCA,PRKCD,PSME3,SHC1,SOS1,TBP 
PI3K/AKT Signaling 4.54 -1.528 AKT1,AKT2,CDKN1B,CTNNB1,GSK3B,ILK,ITGA3,ITGA5,MAP2K1,MAPK1,NRAS,OCRL,PDPK
1,PIK3R3,PPP2R5A,PPP2R5B,PTEN,RAP1A,RRAS,SHC1,SOS1 
cAMP-mediated signaling 1.83 -1.528 ADCY6,AKAP12,CALM1 (includes 
others),CAMK1D,CAMK2D,CREB3,FICD,GABBR2,GDE1,MAP2K1,MAPK1,PDE10A,PDE4A,PD
E7A,PDE7B,PKIA,PPP3CA,PPP3CB,PRKAR2A,RAP1A,RGS10,RGS4 
Angiopoietin Signaling 2.87 -1.508 AKT1,AKT2,BIRC5,CRK,NRAS,PAK2,PIK3R3,RAP1A,RRAS,SOS1,TIE1,TNIP1 
JAK/Stat Signaling 2.16 -1.508 AKT1,AKT2,MAP2K1,MAPK1,NRAS,PIK3R3,RAP1A,RRAS,SHC1,SOS1,STAT2 
Small Cell Lung Cancer Signaling 3.65 -1.414 AKT1,AKT2,APAF1,BID,BIRC2,CDKN1B,CKS1B,MAX,PA2G4,PIK3R3,PTEN,TFDP1,TRAF5 
Insulin Receptor Signaling 2.88 -1.414 AKT1,AKT2,CRK,GSK3B,MAP2K1,MAPK1,MAPK8,NRAS,OCRL,PDPK1,PIK3R3,PRKAR2A,PT
EN,PTPRF,RAP1A,RRAS,SHC1,SOS1 
Ephrin B Signaling 2.04 -1.414 ABI1,AXIN1,CTNNB1,EFNB1,GNB1,GNB4,LIMK1,MAPK1,RHOA,ROCK1 
Acute Phase Response Signaling 1.74 -1.414 AKT1,AKT2,IL6R,IRAK1,MAP2K1,MAP2K4,MAP3K7,MAPK1,MAPK13,MAPK8,NRAS,PDPK1,PI
K3R3,RAP1A,RRAS,SHC1,SOD2,SOS1 
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Table IV- 2 Continued 
NGF Signaling 8.75 
 
-1.4 AKT1,AKT2,CREB3,CRK,MAP2K1,MAP2K4,MAP3K13,MAP3K2,MAP3K3,MAP3K7,MAPK1,MA
PK8,NRAS,PDPK1,PIK3R3,PLCG2,PRKCD,RAP1A,RHOA,ROCK1,RPS6KA2,RRAS,SHC1,SM
PD1,SMPD4,SOS1 
GM-CSF Signaling 4.97 -1.387 AKT1,AKT2,CAMK2D,CSF2RB,ETS1,MAP2K1,MAPK1,NRAS,PIK3R3,PPP3CA,PPP3CB,RAP1
A,RRAS,SHC1,SOS1 
ErbB4 Signaling 4.47 -1.387 AKT1,APH1B,MAP2K1,MAPK1,NRAS,PDPK1,PIK3R3,PLCG2,PRKCA,PRKCD,RAP1A,RRAS,S
HC1,SOS1 
NRF2-mediated Oxidative Stress Response 3.09 -1.387 ABCC1,AKT1,DNAJA3,DNAJB5,DNAJC11,DNAJC9,FKBP5,GSK3B,MAP2K1,MAP2K4,MAP3K7
,MAPK1,MAPK8,NFE2L2,NQO1,NRAS,PIK3R3,PPIB,PRKCA,PRKCD,RAP1A,RRAS,SOD2 
VEGF Family Ligand-Receptor Interactions 2.92 -1.387 AKT1,AKT2,MAP2K1,MAPK1,NRAS,PIK3R3,PLCG2,PRKCA,PRKCD,RAP1A,RRAS,SHC1,SOS
1 
Fcγ Receptor-mediated Phagocytosis in 
Macrophages and Monocytes 
2.48 -1.387 AKT1,AKT2,ARPC1B,ARPC5,CRK,MAPK1,MYO5A,PIK3R3,PLD1,PLD2,PRKCA,PRKCD,PTEN 
p70S6K Signaling 4.19 -1.342 AKT1,AKT2,BCAP31,EGFR,MAP2K1,MAPK1,NRAS,PDPK1,PIK3R3,PLCB1,PLCG2,PLD1,PPP
2R5A,PPP2R5B,PRKCA,PRKCD,RAP1A,RRAS,SHC1,SOS1 
Leptin Signaling in Obesity 1.54 -1.342 ADCY6,AKT1,AKT2,MAP2K1,MAPK1,PIK3R3,PLCB1,PLCG2,PRKAR2A 
NF-κB Activation by Viruses 4.12 -1.291 AKT1,AKT2,ITGA3,ITGA5,ITGA6,ITGAV,ITGB3,MAPK1,NRAS,PIK3R3,PRKCA,PRKCD,RAP1A,
RRAS,TBP 
FLT3 Signaling in Hematopoietic Progenitor 
Cells 
4.05 -1.291 AKT1,AKT2,CREB3,MAP2K1,MAPK1,MAPK13,NRAS,PDPK1,PIK3R3,RAP1A,RPS6KA2,RRAS,
SHC1,SOS1,STAT2 
Regulation of eIF4 and p70S6K Signaling 3.04 -1.291 AKT1,AKT2,EIF2S3,EIF3D,EIF4EBP2,ITGA3,ITGA5,MAP2K1,MAPK1,MAPK13,MKNK1,NRAS,
PDPK1,PIK3R3,PPP2R5A,PPP2R5B,RAP1A,RRAS,SHC1,SOS1 
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Table IV- 2 Continued 
HGF Signaling 7.65 -1.279 AKT1,AKT2,ELF2,ETS1,HGF,ITGA3,ITGA5,MAP2K1,MAP2K4,MAP3K13,MAP3K2,MAP3K3,MA
P3K7,MAPK1,MAPK8,MET,NRAS,PIK3R3,PLCG2,PRKCA,PRKCD,RAP1A,RRAS,SOS1 
Sirtuin Signaling Pathway 2.39 -1.279 ABCA1,AKT1,ATG4D,ATP5F1B,G6PD,GSK3B,GTF3C2,H3F3A/H3F3B,MAPK1,MAPK6,MYCN,
NDUFA5,NDUFAF1,NEDD4,NFE2L2,NQO1,PGAM1,PPARG,RBBP8,SIRT1,SIRT3,SOD2,TIMM
17B,TSPO,TUBA1B,TUBA1C,UQCRC2,VDAC1,XRCC6 
IL-2 Signaling 3.12 -1.265 AKT1,AKT2,MAP2K1,MAPK1,MAPK8,NRAS,PIK3R3,RAP1A,RRAS,SHC1,SOS1 
Relaxin Signaling 2.54 -1.265 ADCY6,AKT1,AKT2,FICD,GDE1,GNB1,GNB4,MAP2K1,MAPK1,NPR2,PDE10A,PDE4A,PDE7A,
PDE7B,PIK3R3,PRKAR2A,RAP1A,SLC39A7 
Systemic Lupus Erythematosus In B Cell 
Signaling Pathway 
3.4 -1.257 AKT1,AKT2,CALM1 (includes 
others),CARD11,CSK,CTNNB1,GSK3B,IL6R,IRAK1,IRAK4,MAP2K1,MAP3K7,MAPK1,NRAS,O
CRL,PDPK1,PIK3R3,PLCG2,PPP3CA,PPP3CB,PRKCA,PRKCD,RAP1A,RRAS,SHC1,SHC2,SH
E,SOS1,STAT2,TICAM1,TRAF5 
ErbB2-ErbB3 Signaling 4.06 -1.155 AKT1,CDKN1B,GSK3B,MAP2K1,MAPK1,NRAS,PDPK1,PIK3R3,PTEN,RAP1A,RRAS,SHC1,SO
S1 
Role of NANOG in Mammalian Embryonic 
Stem Cell Pluripotency 
3.23 -1.155 AKT1,AKT2,AXIN1,BMP1,CTNNB1,FZD1,FZD6,GSK3B,MAP2K1,MAPK1,NRAS,PIK3R3,RAP1
A,RRAS,SHC1,SMAD9,SOS1 
SPINK1 General Cancer Pathway 3.2 -1.155 AKT1,AKT2,EGFR,IL6R,MAP2K1,MAPK1,MT1E,MT1X,NRAS,PIK3R3,RAP1A,RRAS 
Prolactin Signaling 2.58 -1.155 MAP2K1,MAPK1,NRAS,PDPK1,PIK3R3,PLCG2,PRKCA,PRKCD,RAP1A,RRAS,SHC1,SOS1 
Type II Diabetes Mellitus Signaling 2.03 -1.155 ADIPOR2,AKT1,AKT2,CACNG8,MAP2K4,MAP3K7,MAPK1,MAPK8,PDPK1,PIK3R3,PPARG,PR
KCA,PRKCD,SLC27A1,SMPD1,SMPD4 
RhoA Signaling 1.54 -1.155 ANLN,ARPC1B,ARPC5,CIT,LIMK1,MSN,NEDD4,PI4KA,PIP4K2C,PLD1,RHOA,ROCK1,WASF1 
Glioma Signaling 9.11 -1.147 AKT1,AKT2,CALM1 (includes 
others),CAMK1D,CAMK2D,CDKN2C,CDKN2D,E2F2,E2F6,EGFR,IDH3G,IGF2R,MAP2K1,MAP
K1,NRAS,PA2G4,PIK3R3,PLCG2,PRKCA,PRKCD,PTEN,RAP1A,RRAS,SHC1,SOS1,TFDP1 
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Table IV- 2 Continued  
Remodeling of Epithelial Adherens Junctions 3.78 -1.134 ARPC1B,ARPC5,CTNNA1,CTNNB1,CTNND1,EXOC2,HGF,MAPRE1,MET,RAB5B,TUBA1B,TU
BA1C,TUBB4B 
PFKFB4 Signaling Pathway 1.77 -1.134 CREB3,HK1,HK2,MAP2K1,MAP2K4,MAPK1,PRKAR2A 
Neurotrophin/TRK Signaling 4.52 -1.069 AKT1,CREB3,FRS2,MAP2K1,MAP2K4,MAPK1,MAPK8,NRAS,PDPK1,PIK3R3,RAP1A,RRAS,S
HC1,SOS1,SPRY2 
Renal Cell Carcinoma Signaling 4.24 -1.069 AKT1,AKT2,ARNT,CRK,ETS1,HGF,MAP2K1,MAPK1,MET,NRAS,PAK2,PIK3R3,RAP1A,RRAS,
SOS1 
Integrin Signaling 6.44 -1.061 AKT1,AKT2,ARF1,ARHGAP26,ARPC1B,ARPC5,CRK,CTTN,GSK3B,ILK,ITGA10,ITGA11,ITGA3
,ITGA5,ITGA6,ITGAV,ITGB3,MAP2K1,MAP2K4,MAPK1,MAPK8,NRAS,PAK2,PIK3R3,PLCG2,P
TEN,RAP1A,RHOA,RHOBTB1,ROCK1,RRAS,SHC1,SOS1 
Non-Small Cell Lung Cancer Signaling 6.81 -1 AKT1,AKT2,EGFR,ITPR1,ITPR2,MAP2K1,MAPK1,NRAS,PA2G4,PDPK1,PIK3R3,PRKCA,RAP1
A,RASSF1,RRAS,SOS1,STK4,TFDP1 
Telomerase Signaling 5.43 -1 AKT1,AKT2,EGFR,ELF2,ETS1,HDAC1,HDAC3,HDAC5,HDAC8,MAP2K1,MAPK1,NRAS,PDPK1
,PIK3R3,PPP2R5A,PPP2R5B,RAP1A,RRAS,SHC1,SOS1 
P2Y Purigenic Receptor Signaling Pathway 3.34 -1 ADCY6,AKT1,AKT2,CREB3,GNB1,GNB4,ITGB3,MAP2K1,MAPK1,NRAS,PIK3R3,PLCB1,PLCG
2,PRKAR2A,PRKCA,PRKCD,RAP1A,RRAS 
Lymphotoxin β Receptor Signaling 3.04 -1 AKT1,AKT2,APAF1,BIRC2,CASP3,MAPK1,PDPK1,PIK3R3,TRAF5,VCAM1 
Amyloid Processing 2.58 -1 AKT1,AKT2,APH1B,BACE1,CDK5R1,GSK3B,MAPK1,MAPK13,PRKAR2A 
Gα12/13 Signaling 2.39 -1 AKT1,AKT2,CDH2,CDH5,CTNNB1,MAP2K1,MAP2K4,MAPK1,MAPK8,MEF2C,NRAS,PIK3R3,R
AP1A,RHOA,ROCK1,RRAS 
Estrogen-Dependent Breast Cancer 
Signaling 
1.95 -1 AKT1,AKT2,CREB3,EGFR,HSD17B12,MAPK1,NRAS,PIK3R3,RAP1A,RRAS 
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Table IV- 2 Continued 
ILK Signaling 1.76 -1 AKT1,AKT2,CASP3,CREB3,CTNNB1,DSP,GSK3B,ILK,ITGB3,MAP2K4,MAPK1,MAPK8,PDPK1,
PIK3R3,PPP2R5A,PPP2R5B,PTEN,RHOA,RHOBTB1 
Mouse Embryonic Stem Cell Pluripotency 4.54 -0.943 AKT1,AKT2,AXIN1,CTNNB1,DVL2,FZD1,FZD6,GSK3B,MAP2K1,MAP3K7,MAPK1,MAPK13,NR
AS,PIK3R3,RAP1A,RRAS,SMAD9,SOS1 
Cholecystokinin/Gastrin-mediated Signaling 4.19 -0.943 EGFR,ITPR1,ITPR2,MAP2K1,MAP2K4,MAPK1,MAPK8,MEF2C,NRAS,PLCB1,PRKCA,PRKCD,
RAP1A,RHOA,RHOBTB1,ROCK1,RRAS,SHC1,SOS1 
Actin Nucleation by ARP-WASP Complex 3.03 -0.905 ARPC1B,ARPC5,ITGA3,ITGA5,NRAS,RAP1A,RHOA,RHOBTB1,ROCK1,RRAS,SOS1,WASF1 
Thrombopoietin Signaling 3 -0.905 MAP2K1,MAPK1,NRAS,PIK3R3,PLCG2,PRKCA,PRKCD,RAP1A,RRAS,SHC1,SOS1 
Regulation of Actin-based Motility by Rho 2.05 -0.905 ARPC1B,ARPC5,ITGA3,ITGA5,LIMK1,PAK2,PI4KA,PIP4K2C,RHOA,RHOBTB1,ROCK1,WASF
1 
iCOS-iCOSL Signaling in T Helper Cells 1.87 -0.905 AKT1,AKT2,CALM1 (includes 
others),CAMK2D,CSK,ITPR1,ITPR2,PDPK1,PIK3R3,PPP3CA,PPP3CB,PTEN,SHC1 
Nitric Oxide Signaling in the Cardiovascular 
System 
1.51 -0.905 AKT1,AKT2,CALM1 (includes 
others),ITPR1,ITPR2,MAP2K1,MAPK1,PIK3R3,PRKAR2A,PRKCA,PRKCD 
Cardiac β-adrenergic Signaling 1.44 -0.905 ADCY6,AKAP12,FICD,GDE1,GNB1,GNB4,PDE10A,PDE4A,PDE7A,PDE7B,PKIA,PPP2R5A,PP
P2R5B,PRKAR2A 
Neuroinflammation Signaling Pathway 3.39 -0.898 ACVR1B,AKT1,AKT2,APH1B,BACE1,BIRC2,BIRC5,CASP3,CREB3,CTNNB1,FAS,FZD1,GABB
R2,GSK3B,IL6R,IRAK1,IRAK4,MAP2K4,MAPK1,MAPK13,MAPK6,MAPK8,NFE2L2,PIK3R3,PLC
G2,PPP3CA,PPP3CB,SOD2,TGFBR1,TGFBR2,TGFBR3,TICAM1,VCAM1 
Osteoarthritis Pathway 1.85 -0.894 ANKH,CASP3,CREB3,CTNNA1,CTNNB1,DKK1,FZD1,FZD6,HDAC3,IL1RL1,ITGA3,ITGA5,MEF
2C,OCRL,PPARG,SDC4,SIRT1,SMAD9,TGFBR1,TGFBR2,TIMP3 
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Table IV- 2 Continued 
Glioblastoma Multiforme Signaling 6.42 -0.853 AKT1,AKT2,AXIN1,CDKN1B,CTNNB1,E2F2,E2F6,EGFR,FZD1,FZD6,GSK3B,ITPR1,ITPR2,MA
P2K1,MAPK1,NF1,NRAS,PIK3R3,PLCB1,PLCG2,PRKCD,PTEN,RAP1A,RHOA,RHOBTB1,RRA
S,SHC1,SOS1 
VEGF Signaling 3.14 -0.832 AKT1,AKT2,ARNT,EIF2S3,MAP2K1,MAPK1,NRAS,PIK3R3,PLCG2,PRKCA,RAP1A,ROCK1,RR
AS,SHC1,SOS1 
Corticotropin Releasing Hormone Signaling 2.67 -0.832 ADCY6,ARPC5,CACNG8,CALM1 (includes 
others),CREB3,ITPR1,ITPR2,MAP2K1,MAPK1,MAPK13,MEF2C,NPR2,PLCG2,PRKAR2A,PRK
CA,PRKCD,RAP1A,SLC39A7 
IGF-1 Signaling 2.51 -0.832 AKT1,AKT2,MAP2K1,MAPK1,MAPK8,NEDD4,NRAS,PDPK1,PIK3R3,PRKAR2A,RAP1A,RRAS,
SHC1,SOS1 
Cdc42 Signaling 1.71 -0.832 ARPC1B,ARPC5,DIAPH3,EXOC2,EXOC3,EXOC4,GSK3B,IQGAP3,ITGA3,ITGA5,LIMK1,LLGL1
,MAP2K4,MAPK1,MAPK13,MAPK8,PAK2 
Leukocyte Extravasation Signaling 4.4 -0.816 CDH5,CRK,CTNNA1,CTNNB1,CTNND1,CTTN,ITGA3,ITGA5,ITGA6,ITGB3,JAM3,MAP2K4,MA
PK1,MAPK13,MAPK8,MMP14,MSN,PIK3R3,PLCG2,PRKCA,PRKCD,RAP1A,RHOA,ROCK1,SE
LPLG,TIMP3,VCAM1 
Signaling by Rho Family GTPases 2.95 -0.816 ARPC1B,ARPC5,CDH2,CDH5,CIT,DIAPH3,GNB1,GNB4,ITGA3,ITGA5,LIMK1,MAP2K1,MAP2K
4,MAPK1,MAPK8,MSN,NEDD4,PAK2,PI4KA,PIK3R3,PIP4K2C,PLD1,RHOA,RHOBTB1,ROCK1
,STMN1,WASF1 
IL-8 Signaling 4.8 -0.784 AKT1,AKT2,CSTB,EGFR,GNB1,GNB4,IRAK1,IRAK4,ITGAV,ITGB3,LIMK1,MAP2K1,MAP2K4,M
APK1,MAPK8,NRAS,PAK2,PIK3R3,PLD1,PLD2,PRKCA,PRKCD,RAP1A,RHOA,RHOBTB1,RO
CK1,RRAS,VCAM1 
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Table IV- 2 Continued 
TGF-β Signaling 4.39 -0.775 ACVR1B,HDAC1,MAP2K1,MAP2K4,MAP3K7,MAPK1,MAPK13,MAPK8,NRAS,RAP1A,RNF111,
RRAS,SMAD9,SOS1,TGFBR1,TGFBR2,ZFYVE9 
Aldosterone Signaling in Epithelial Cells 3 -0.775 DNAJB5,DNAJC11,DNAJC9,HSPA13,HSPA9,ICMT,ITPR1,ITPR2,MAP2K1,MAPK1,NEDD4,PD
PK1,PI4KA,PIK3R3,PIP4K2C,PLCB1,PLCG2,PRKCA,PRKCD,SOS1 
HMGB1 Signaling 1.47 -0.775 AKT1,AKT2,KAT2B,MAP2K1,MAP2K4,MAPK1,MAPK13,MAPK8,NRAS,PIK3R3,PLAT,RAP1A,R
HOA,RHOBTB1,RRAS,VCAM1 
STAT3 Pathway 3.45 0.5 CDC25A,CSF2RB,EGFR,HGF,IGF2R,IL17RC,IL1RL1,IL6R,MAP2K1,MAP2K4,MAPK1,MAPK13,
MAPK8,NRAS,RAP1A,RRAS,TGFBR1,TGFBR2,TGFBR3 
BMP signaling pathway 3.93 0.535 BMP1,FST,MAGED1,MAP2K1,MAP2K4,MAP3K7,MAPK1,MAPK13,MAPK8,NRAS,PRKAR2A,R
AP1A,RRAS,SMAD9,SOS1 
ERK/MAPK Signaling 5.05 0.577 ATF1,CREB3,CRK,ELF2,ETS1,H3F3A/H3F3B,ITGA3,ITGA5,MAP2K1,MAPK1,MKNK1,MKNK2,
MYCN,NRAS,PAK2,PIK3R3,PLCG2,PPARG,PPP2R5A,PPP2R5B,PRKAR2A,PRKCA,PRKCD,R
AP1A,RRAS,SHC1,SOS1,VRK2 
Sumoylation Pathway 2.55 0.577 CTBP1,ETS1,FAS,HDAC1,MAP2K4,MAPK8,RAN,RFC1,RHOA,RHOBTB1,RNF4,SENP3,SIRT 
PPARα/RXRα Activation 4.29 0.626 ABCA1,ACOX1,ACVR1B,ADCY6,ADIPOR2,IL1RL1,MAP2K1,MAP2K4,MAP3K7,MAPK1,MAPK8
,MED12,MEF2C,NRAS,PLCB1,PLCG2,PRKAR2A,PRKCA,RAP1A,RRAS,SHC1,SLC27A1,SOS
1,TGFBR1,TGFBR2,TGFBR3 
NF-κB Signaling 3.46 0.626 AKT1,AKT2,BTRC,CARD11,EGFR,GSK3B,HDAC1,IGF2R,IRAK1,IRAK4,MAP3K3,MAP3K7,MA
PK8,NRAS,PIK3R3,PLCG2,RAP1A,RRAS,TGFBR1,TGFBR2,TGFBR3,TNIP1,TRAF5 
Endothelin-1 Signaling 3.22 0.626 ADCY6,CASP3,ITPR1,ITPR2,MAPK1,MAPK13,MAPK6,MAPK8,NRAS,PIK3R3,PLCB1,PLCG2,
PLD1,PLD2,PRKCA,PRKCD,PTGS1,RAP1A,RRAS,SHC1,SHC2,SHE,SOS1 
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Table IV- 2 Continued 
Cyclins and Cell Cycle Regulation 5.42 0.632 BTRC,CDC25A,CDKN1B,CDKN2C,CDKN2D,E2F2,E2F6,GSK3B,HDAC1,HDAC3,HDAC5,HDA
C8,PA2G4,PPP2R5A,PPP2R5B,SKP1,TFDP1 
UVA-Induced MAPK Signaling 4.28 0.632 CASP3,EGFR,MAP2K4,MAPK1,MAPK13,MAPK8,NRAS,PARP2,PIK3R3,PLCB1,PLCG2,PRKC
A,RAP1A,RPS6KA2,RRAS,SMPD1,SMPD4 
IL-1 Signaling 1.75 0.707 ADCY6,GNB1,GNB4,IRAK1,IRAK4,MAP2K4,MAP3K7,MAPK1,MAPK13,MAPK8,PRKAR2A 
Apoptosis Signaling 4.22 0.728 APAF1,BAK1,BID,BIRC2,CASP3,DFFA,FAS,MAP2K1,MAP2K4,MAPK1,MAPK8,NRAS,PLCG2,
PRKCA,RAP1A,ROCK1,RRAS 
GP6 Signaling Pathway 3.23 0.728 AKT1,AKT2,CALM1 (includes 
others),COL21A1,COL27A1,COL5A2,COL6A2,COL8A1,GSK3B,ITGB3,ITPR1,LAMA4,PDPK1,PI
K3R3,PLCG2,PRKCA,PRKCD 
Paxillin Signaling 5.3 0.775 ARF1,CRK,CSK,ITGA10,ITGA11,ITGA3,ITGA5,ITGA6,ITGAV,ITGB3,MAP2K4,MAPK1,MAPK13
,MAPK8,NRAS,PAK2,PIK3R3,RAP1A,RRAS,SOS1 
ATM Signaling 2.8 0.832 ATF1,BID,CBX1,CDC25A,CDC25C,CREB3,H2AFX,MAP2K4,MAPK13,MAPK8,PPP2R5A,PPP2
R5B,RBBP8,SMC1A 
Ceramide Signaling 2.74 0.905 AKT1,AKT2,MAP2K1,MAP2K4,MAPK8,NRAS,PIK3R3,PPP2R5A,PPP2R5B,RAP1A,RRAS,SMP
D1,SMPD4 
PTEN Signaling 6.55 1.043 AKT1,AKT2,CASP3,CDKN1B,EGFR,GSK3B,IGF2R,ILK,ITGA3,ITGA5,MAP2K1,MAPK1,NRAS,
OCRL,PDPK1,PIK3R3,PTEN,RAP1A,RRAS,SHC1,SOS1,TGFBR1,TGFBR2,TGFBR3 
Renin-Angiotensin Signaling 5.89 1.091 ACE,ADCY6,ITPR1,ITPR2,MAP2K1,MAP2K4,MAPK1,MAPK13,MAPK8,NRAS,PAK2,PIK3R3,PL
CG2,PRKAR2A,PRKCA,PRKCD,RAP1A,RRAS,SHC1,SHC2,SHE,SOS1 
p53 Signaling 3.74 1.291 AKT1,AKT2,APAF1,BIRC5,CTNNB1,FAS,GNL3,GSK3B,HDAC1,KAT2B,MAPK8,PIK3R3,PTEN,
SIRT1,TNFRSF10B,TP53I3 
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Table IV- 2 Continued 
RhoGDI Signaling 1.71 1.291 ARPC1B,ARPC5,CDH2,CDH5,GNB1,GNB4,ITGA3,ITGA5,LIMK1,MSN,PAK2,PI4KA,PIP4K2C,P
RKCA,RHOA,RHOBTB1,ROCK1,WASF1 
Induction of Apoptosis by HIV1 2.05 1.414 APAF1,BAK1,BID,BIRC2,CASP3,DFFA,FAS,MAP2K4,MAPK8 
Neuropathic Pain Signaling In Dorsal Horn 
Neurons 
1.46 1.508 CAMK1D,CAMK2D,ITPR1,ITPR2,MAPK1,PIK3R3,PLCB1,PLCG2,PRKAR2A,PRKCA,PRKCD 
TNFR1 Signaling 1.58 1.89 APAF1,BID,BIRC2,CASP3,MAP2K4,MAPK8,PAK2 
 
 88 
Chapter V 
MICRORNA-126 REGULATES HUMAN MICROVASCULAR ENDOTHELIAL CELL 
FUNCTION VIA SLC7A5-MTOR SIGNALING AXIS5 
Introduction 
As we demonstrated in Chapter IV that miR-126 is a negative regulator of mTOR 
signaling in HLMVEC, one key question that remained unanswered was through what 
mechanism did miR-126 affect mTOR activity. mTOR responds to a diverse set of 
environmental signals such as amino acids and growth factors and is known be particularly 
sensitive to amino acids such as L-leucine and L-glutamine99, 130. We have established that a 
main miR-126 target in HLMVEC is SLC7A5 (Fig IV-3B-C), a membrane antiporter which 
mediates the uptake of leucine by exporting intracellular L-glutamine and subsequently leads to 
activation of mTOR61, 130. We therefore hypothesized that miR-126 can prevent mTOR activation 
by inhibiting SLC7A5 expression. 
Upon activation, mTOR dictates the biosynthesis of macromolecules required for cell 
growth and promotes cell proliferation, a critical process required for angiogenesis in vivo20, 40. In 
addition, in order to prevent premature degradation of the newly synthesized molecules, mTOR 
concomitantly inhibits autophagy137, a process in which cytoplasmic contents are being 
 
5 Portions of this chapter were previously published in Arteriosclerosis, Thrombosis, and 
Vascular Biology and are included with the permission of the copyright holder.  
Citation: Cao D et al., Arterioscler Thromb Vasc Biol. 2020;40:1195-1206  
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degraded and recycled by lysosomes. Our group has previously shown that aberrant autophagy 
causes endothelial cell death during stress conditions139. Based on this knowledge, we aimed to 
address whether the SLC7A5-mTOR signaling is responsible for the anti-angiogenic, pro-
apoptotic functions of miR-126. 
Objectives  
• Determine whether miR-126 regulates mTOR signaling via SLC7A5 
• Determine whether miR-126-KD promotes cell proliferation via SLC7A5 
• Determine whether miR-126-KD reduces cell apoptosis via SLC7A5 
• Determine whether miR-126 regulates autophagy 
Results 
miR-126 regulates mTOR via SLC7A5 in HLMVEC 
To determine whether SLC7A5 was required for mTOR activation in HLMVEC, we first 
treated control and 126-KD HLMVEC with JPH203 (10µM or 20µM, 4hrs), a pharmacological 
inhibitor of SLC7A5. We found that JPH203 dose-dependently reduced S6 activity in 126-KD 
cells (Fig V-1A). To rule out the possible off-target effects of JPH203, we performed a co-
transfection of antisense miR-126 (5nM, 16hrs) and SLC7A5 siRNA (10nM, 16hrs). The co-
transfection effectively reduced miR-126 and SLC7A5 levels relative to non-targeting controls 
(Chapter II, Fig II-B-C), and similar to JPH203, markedly inhibited S6 phosphorylation compared 
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to cells transfected with 126-KD alone (Fig V-1B), suggesting that the inhibition of miR-126 
activates mTOR signaling in a SLC7A5-dependent fashion.  
miR-126 knockdown promotes HLMVEC proliferation via SLC7A5 
To determine whether the growth-promoting effect of 126-KD we observed (Chapter III, 
Fig III-1A) was due to mTOR activation, HLMVEC were transfected with non-targeting controls 
or antisense miR-126 inhibitors at 5nM each for 16 hours, and subsequently re-plated at equal 
numbers in growth medium with or without mTOR inhibitor rapamycin (1nM). The number of live 
cells in each condition were counted after 24, 48, and 72 hours using a hematocytometer and 
plotted as a growth curve. In addition, at 24 hours, we assessed Ki67 expression using 
immunofluorescence. We found that compared to the non-targeting control, 126-KD significantly 
increased both the number of live cells and Ki67 positive cells; however, these effects were 
remarkably reduced when rapamycin was present (Fig V-2), suggesting that the proliferative 
effect of 126-KD is mTOR dependent. To ascertain if the proliferative effect of 126-KD is 
mediated through the SLC7A5-mTOR axis, HLMVEC co-transfected with miR-126 antisense 
inhibitors and SLC7A5 siRNA (5nM and 10nM respectively, 16hrs) were seeded at the same 
number as controls and, cell proliferation was determined by growth curve and Ki67 staining. 
Compared to cells transfected with 126-KD alone, which exhibited a high proliferation rate, cells 
co-transfected with both miR-126 inhibitor and SLC7A5 siRNA demonstrated a much lower 
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proliferation rate, as indicated by lower numbers of Ki67 positive cells (by ~90%) and live cells 
overall (by ~50%)(Fig V-3).  
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Figure V- 1. Effects of 126-KD on SLC7A5-mediated mTOR signaling.  
A-B. Activity of S6 in cells with 126-KD after treatment with SLC7A5 inhibitor JPH203 (10µM or 
20µM, 4hrs, B) or after co-transfection with SLC7A5 siRNA (10nM, 16hrs, C). Top: 
representative Western blot images. Bottom: Densitometry quantification of S6 phosphorylation. 
Results presented as mean ± SEM; *p<0.05; **p<0.01; ****p<0.0001; One-way ANOVA followed 
by Tukey’s post-hoc multiple comparisons. Each data point represents an individual experiment; 
At least three induvial donors were used per assay to eliminate the contribution of donor-specific 
effects. 
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Figure V- 2. The role of mTOR signaling in miR-126-regulated cell proliferation.  
A. Growth curve demonstrated by live cell count of HLMVEC treated with rapamycin (1nM) for 
24, 48, or 72hrs. B. Left: representative IF images of HLMVEC stained for Ki67 (green) and 
DAPI (blue). Scale bar: 50µm. Right: quantification of Ki67 expression by first normalizing Ki67 
positive cells to the total number of cells (DAPI) and then to the Ctrl condition. 10 images were 
analyzed per transfection condition per individual experiment. Results presented as mean ± 
SEM; One-way ANOVA followed by Tukey’s post-hoc multiple comparisons was performed for 
each time point in A. Two-way ANOVA was performed for analyses in B. *p<0.05; **p<0.01; 
Each data point represents an individual experiment; At least three induvial donors were used 
per assay to eliminate the contribution of donor-specific effects. 
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Figure V- 3. The role of SLC7A5 in miR-126-regulated cell proliferation. 
A. Growth rate indicated by live cell counts at 24, 48, and 72hrs. B. Left: representative IF 
images of HLMVEC stained for Ki67 (green) and DAPI (blue). Scale bar: 50µm. Right: 
quantification of Ki67 expression by first normalizing Ki67 positive cells to the total number of 
cells (DAPI) and then to the Ctrl condition. 10 images were analyzed per transfection condition 
per individual experiment. Results presented as mean ± SEM; *p<0.05; **p<0.01; ****p<0.0001; 
One-way ANOVA followed by Tukey’s post-hoc multiple comparisons. Each data point 
represents an individual experiment; At least three induvial donors were used per assay to 
eliminate the contribution of donor-specific effects. 
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miR-126 does not regulate cell apoptosis via SLC7A5 
We next assessed whether the protective effect of 126-KD on cell baseline apoptosis 
was also mediated through SLC7A5. Using Western blot, we measured the levels of cleaved-
PARP in 126-KD alone and 126-KD and siSLC7A5 co-transfected HLMVEC. Interestingly, 
siSLC7A5 alone did not appear to affect baseline apoptosis as compared to non-targeting 
controls. We also did not observe any difference in cleaved-PARP levels between 126-KD alone 
and the co-transfected condition (Fig V-4). These results indicate that SLC7A5 may not be 
involved in the anti-apoptotic effect of miR-126 knockdown. 
miR-126 does not affect cell autophagy 
Lastly, we sought to determine if miR-126 influences autophagy in HLMVEC, considering 
that mTOR is a potent inhibitor of autophagy93. We measured using Western blot the expression 
of Atg5 and Atg7, which are important for autophagy elongation and autophagosome formation, 
and p62, which is commonly used as an indicator of successful autophagosome and lysosome 
fusion111. We detected no difference in the expression of Atg5, Atg7, and p62 in control vs. 126-
OE or 126-KD HLMVEC (Fig V-5), indicating that the effect of miR-126 on cell survival may not 
involve autophagy. 
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Figure V- 4. The role of SLC7A5 in miR-126-mediated cell apoptosis.  
Cell apoptosis indicated by Western blot measurement of cleaved-PARP. Results presented as 
mean ± SEM; No statistical significance was detected using One-way ANOVA followed by 
Tukey’s post hoc test. Each data point represents an individual experiment; At least three 
induvial donors were used per assay to eliminate the contribution of donor-specific effects. 
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Figure V- 5. Effect of miR-126 on HLMVEC autophagy.  
Cell autophagy determined by Atg7, Atg5, and SQSTM1 (p62) levels. Left: representative 
Western blot image. Right three: densitometry quantification normalizing to vinculin. All results 
presented as mean ± SEM; No statistical significance detected between conditions using One-
way ANOVA followed by Dunnett’s multiple comparisons test. Each data point represents an 
individual experiment; At least three induvial donors were used per assay to eliminate the 
contribution of donor-specific effects. 
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Discussion 
In this chapter, we provided an important mechanistic link between miR-126 function and 
the SLC7A5-mTOR signaling axis that the negatively effect of miR-126 on mTOR signaling was 
mediated by SLC7A5 and that the proliferative phenotype of 126-KD was dependent on 
disinhibition of SLC7A5 and subsequent mTOR activation (Fig V-6). Our results is high 
consistent with previous findings that amino acid uptake mediated by SLC7A5 is rate limiting for 
mTOR activation and the inhibition of SLC7A5 function or expression can severely impede cell 
growth130, 171. We showed that SLC7A5 knockdown abrogated the growth promoting effect of 
126-KD by more than 90% indicated by Ki67 staining, suggesting that SLC7A5 is a major 
contributor to the effect of miR-126 on cell proliferation. However, it remains unknown whether 
the beneficial effect of 126-KD on HLMVEC tube formation we described in Chapter III (Fig III-
1B) is also mediated through SLC7A5, which should be addressed in future studies.  
Our finding that 126-KD reduced cell apoptosis independent of SLC7A5 indicates that 
SLC7A5 may not mediate all miR-126-induced effects in HLMVEC. Also, despite the key role of 
mTOR in regulating autophagy 130, 172, there was no change in autophagy initiation and 
elongation, indicated by unaltered Atg5 and Atg7 levels, as well as in the formation and 
degradation autophagosomes by lysosomes, indicated by unchanged p62 levels following 126-
OE or 126-KD. These results suggest engagement of alternative mechanisms in miR-126-
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mediated cell apoptosis. The top candidates, based on our IPA pathway analysis (Table IV-2), 
may involve ceramide, PTEN and p53, and/or TNFR1 signaling pathways, which were all 
markedly activated by high miR-126 level, and previously shown to be involved in the induction 
of programmed cell death 91, 173, 174.   
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Figure V- 6. Summary of findings. 
A schematic of the role of miR-126 in human lung microvascular endothelial cells (HLMVEC). 
Upregulation of miR-126 in HLMVEC increases baseline apoptosis, in a solute carrier family 7 
member 5 (SLC7A5) - independent manner, and decreases cell proliferation and angiogenesis, 
by inhibiting SLC7A5, which subsequently prevents activation of mammalian target of 
rapamycin complex 1(mTORC1). Figure adopted from Cao D et al., 202034.   
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CHAPTER VI  
CONCLUSIONS AND FUTURE DIRECTIONS 
Key findings and broader implications  
In this thesis we show that miR-126 negatively regulates HLMVEC proliferation, 
angiogenesis and induces apoptosis during homeostasis, whereas miR-126 knockdown drives a 
pro-angiogenic and anti-apoptotic phenotype which is protective against cell death and 
impairment of endothelial function during CS exposure (Chapter III). In HLMVEC, miR-126 
directly targets SLC7A5 and ADMA9 and promotes an anti-angiogenic and pro-apoptotic 
transcriptomic profile characterized by inhibition of mTOR but not VEGF signaling pathway 
(Chapter IV). While the inhibitory effect of miR-126 on HLMVEC proliferation is mediated 
through the SLC7A5-mTOR signaling axis, its pro-apoptotic function is independent of mTOR 
and is not caused by cell autophagy (Chapter V).  
We demonstrate in this study a cell type-specific role of miR-126 involving negative 
regulation of distinct targets and pathways essential for angiogenesis and cell survival. These 
findings may provide a new paradigm for vascular bed-specific therapeutic targeting of lung 
diseases that involve either excessive loss of the microvasculature (e.g. emphysema and 
pulmonary hypertension) or exuberant microvascular angiogenesis (e.g. hereditary hemorrhagic 
telangiectasia and lung cancer). 
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Future Directions 
Role of miR-126-ADAM9 axis in HLMVEC 
We identified in this study that in addition to SLC7A5, ADAM9 is another direct target of 
miR-126. We detected that mir-126 exerts a negative effect on the expression of both the 
transmembrane and the secreted forms of ADAM9. ADAM9 plays an important role in 
endothelial cell migration and proliferation by directly interacting with components of the ECM 
(i.e. integrin) and by promoting the interaction between growth factors and their membrane 
receptors59, 175. It has been reported that an increase in ADAM9 contributes to the progression of 
oxygen-induced retinopathy (OIR) and CNV176, both of which are diseases characterized by 
excessive neovascularization. Interestingly, other research groups have shown that these two 
pathological conditions can be alleviated by local injection of miR-12627, 36. miR-126 is 
decreased in various cancer cell types to promote growth and metastasis through disinhibition 
of ADAM9, which leads to cell mobility and growth factor receptor activation56. Whether miR-126 
engages this mechanism to regulate microvascular endothelial cell function has not yet been 
studied. It is probable that the miR-126-ADAM9 axis contributes to the inhibitory effects of miR-
126 on HLMVEC proliferation and angiogenesis by suppressing EGF or FGF signaling 
pathways based on these findings, and the results from our IPA analysis suggesting that FGF 
and EGF signaling pathways were negatively associated with high levels of miR-126. However, 
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ADAM9 may not play a major role in the miR-126-induced apoptosis since inhibition of EGFR 
signaling alone did not seem to be sufficient to cause endothelial cell death. These hypotheses 
could be easily tested in the future by measuring cell proliferation, tube formation, apoptosis, 
and EGF- or FGF-mediated ERK and AKT activation in HLMVEC knocked down simultaneously 
for miR-126 and ADAM9.  
Mechanism of miR-126-induced apoptosis 
Our results from Chapter V suggest that the pro-apoptotic effect of mir-126 in HLMVEC 
is independent of SLC7A5. This observation was unexpected to us given that mTOR inhibition is 
sufficient to cause cancer cell death177, 178, and did not support our initial hypothesis that the 
induction of apoptosis by miR-126 could be a result of SLC7A5-mediated mTOR inhibition. We 
revisited our IPA analysis to look for alternative candidates and found that pathways known to 
be involved in the induction of programmed cell death 91, 173, 174, including ceramide, PTEN and 
p53, and TNFR1 signaling pathways were highly associated with high miR-126 levels. Future 
validation of these pathways will be crucial in order to decipher the mechanism by which miR-
126 engages to affect cell apoptosis and its downstream targets responsible for this process.  
Effect of miR-126 on autophagy 
Autophagy is a highly regulated and self-degrative process essential for cell survival as 
well as for balancing the sources of nutrient and energy during stress conditions. Serving as the 
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critical determinant for cellular anabolic or catabolic state, mTOR inhibits autophagy upon 
activation by phosphorylating ULK1 and Atg13, which prevents phagophore formation and 
thereby autophagy initiation112. In our study, we found that despite the inhibitory effect on mTOR, 
miR-126 did not influence autophagic activity, as indicated by our results showing unchanged 
autophagy markers including Atg5, Atg7, and p62. One interpretation of this result could be that 
autophagy may not be regulated by mTOR in HLMVEC. Although, this is highly unlikely because 
a previous study in our group showed that rapamycin led to autophagy in HLMVEC139. A key 
experiment needed to reassure this point would be to measure during 126-OE and -KD the 
phosphorylation levels of ULK1 and Atg13, and the protein levels of L3CB, which is directly 
located in the autophagosome membrane. An alternative explanation of our data would be that 
during miR-126 manipulation, endothelial cells are able to engage mTOR-independent 
pathways to maintain autophagy levels unchanged. For instance, recent discoveries have 
revealed that autophagy can be activated in a mTOR-independent manner such as through 
inositol IP3, cAMP, and intracellular Ca
2+ levels110, 113. However, the components and regulatory 
mechanisms of these pathways are still not well-characterized.  
Role of miR-126 in chronic CS exposure-induced emphysema 
Chronic CS exposure causes extensive lung endothelial cell death which contributes to 
the pathogenesis of emphysema, a phenotype of COPD characterized by net loss of alveolar 
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gas exchange area 90. In our study, pre-treatment of HLMVEC with miR-126 inhibitors were 
protective of CS-induced cell death and dysfunction. It remains to be determined if this effect will 
extrapolate to chronic CS-exposed animal models and whether miR-126 depletion following CS 
exposure exerts similar beneficial effects.  
We have previously reported that acute exposure to CS increases the release of miR-
126 within exosomes and decreases the intracellular miR-126 levels in HLMVEC 162. Based on 
previous observations showing that the pro-survival pathways such as mTOR and AKT were 
activated in response to acute CS exposure163, 164, we propose that decreased intracellular miR-
126 is likely an adaptive survival response. It will be interesting to determine if the loss of miR-
126 is solely a result of exosome shedding or inhibition at transcriptional level is also involved, 
by measuring the primary form of miR-126 which will indicate regulation at the transcription 
level. If the latter is true, it would be important to identify the transcription factors in charge and 
their relations to CS. Future studies should explore transcription factors currently known to 
regulate miR-126 expression including ETS1/2 and KLF-268, 69. 
Other key questions that remain unanswered are how chronic CS exposure would affect 
miR-126 levels in the lung endothelial cells and whether miR-126 plays a role in the 
development of CS-induced emphysema. The first question can be addressed by performing 
miR-126 fluorescence in situ hybridization (FISH) in lungs from smokers vs. non-smokers and/or 
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from mice chronically exposed to CS vs. ambient air.  
There has been increasing evidence showing that cellular senescence contributes to the 
development of emphysema179. Alveolar cells including epithelial and endothelial cells in 
patients with emphysema were found to have significantly higher levels of p16 and b-
galactosidase and shorter telomere length compared to non-smoker controls180. The important 
role of mTOR in cellular senescence is well-accepted181, 182. A recent study from Houssaini A and 
colleagues showed that mTOR was activated in endothelial cells isolated from COPD patients 
compared to healthy controls and forced activation of mTOR in mice was sufficient to induced 
lung senescence and emphysema-like injuries183. Considering the effect of miR-126 on mTOR 
that we have discovered, it will be interesting to know whether miR-126 imposes any effect on 
HLMVEC senescence, which could be achieved by assessing senescence markers such as 
p16, p21, and b-galactosidase in 126-OE and -KD HLMVEC and if possible, miR-126 
conditional KO mice. Results from these proposed studies, combined with the knowledge that 
will be gained from assessing miR-126 levels in mouse and human emphysematous lungs, will 
provide important evidence to determine the role of miR-126 in emphysema development.  
Function of miR-126-5p in HLMVEC 
Because the passenger strand of miR-126, miR-126-5p, is also known to regulate 
endothelial angiogenic function33, 49, we confirmed in our study that the levels of miR-126-5p as 
 
 107 
well as its primary targets were not affected by the overexpression or knockdown of miR-126. 
However, this does not rule out the possibility that miR-126-5p may play important roles in 
HLMVEC, since numerous studies have demonstrated that miR-126 and miR-126-5p can 
independently regulate endothelial function by engaging distinct targets and downstream 
pathways33, 66. The function of miR-126-5p in the lung has not been characterized, which could 
be an interesting focus for future studies.  
miR-126 knockout model in vivo 
As in our in vitro knockdown model we were only able to reduce intracellular miR-126 by 
~60% at current concentration (5nM, 16hrs, Fig II-1), it is possible that the functional effects of 
miR-126 we observed were specific to a certain range of miR-126 abundance, especially 
considering the detrimental effects observed by others in the murine miR-126 knockout 
models27, 67. This can be address in future experiments by introducing miRNA CRISPR-cas9 
system in vitro which has recently been established184. However, one important caveat of 
miRNA knockout study is that since both alleles will be lost, it would be difficult to attribute the 
outcome to a specific strand. 
 
 
  
 
 108 
REFERENCES 
1. Bartel DP. Micrornas: Genomics, biogenesis, mechanism, and function. Cell. 
2004;116:281-297 
2. Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, Sohn SY, Cho Y, Zhang BT, Kim VN. 
Molecular basis for the recognition of primary micrornas by the drosha-dgcr8 complex. 
Cell. 2006;125:887-901 
3. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a rangtp-dependent dsrna-binding 
protein that mediates nuclear export of pre-mirnas. RNA. 2004;10:185-191 
4. Song MS, Rossi JJ. Molecular mechanisms of dicer: Endonuclease and enzymatic 
activity. Biochem J. 2017;474:1603-1618 
5. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human 
argonaute2 mediates rna cleavage targeted by mirnas and sirnas. Mol Cell. 
2004;15:185-197 
6. Kawamata T, Seitz H, Tomari Y. Structural determinants of mirnas for risc loading and 
slicer-independent unwinding. Nat Struct Mol Biol. 2009;16:953-960 
7. Ha M, Kim VN. Regulation of microrna biogenesis. Nat Rev Mol Cell Biol. 2014;15:509-
524 
8. Chiang HR, Schoenfeld LW, Ruby JG, Auyeung VC, Spies N, Baek D, Johnston WK, 
Russ C, Luo S, Babiarz JE, Blelloch R, Schroth GP, Nusbaum C, Bartel DP. Mammalian 
micrornas: Experimental evaluation of novel and previously annotated genes. Genes 
Dev. 2010;24:992-1009 
9. Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, 
Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, Tuschl T. A uniform system for 
microrna annotation. RNA. 2003;9:277-279 
 
 109 
10. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the 
assembly of the rnai enzyme complex. Cell. 2003;115:199-208 
11. Wu H, Ye C, Ramirez D, Manjunath N. Alternative processing of primary microrna 
transcripts by drosha generates 5' end variation of mature microrna. PLoS One. 
2009;4:e7566 
12. Bartel DP. Micrornas: Target recognition and regulatory functions. Cell. 2009;136:215-
233 
13. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, 
indicates that thousands of human genes are microrna targets. Cell. 2005;120:15-20 
14. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian 
microrna targets. Cell. 2003;115:787-798 
15. Wong N, Wang X. Mirdb: An online resource for microrna target prediction and functional 
annotations. Nucleic Acids Res. 2015;43:D146-152 
16. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mrnas are conserved 
targets of micrornas. Genome Res. 2009;19:92-105 
17. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, 
Anderson KV, Hannon GJ. Dicer is essential for mouse development. Nat Genet. 
2003;35:215-217 
18. Chong MM, Zhang G, Cheloufi S, Neubert TA, Hannon GJ, Littman DR. Canonical and 
alternate functions of the microrna biogenesis machinery. Genes Dev. 2010;24:1951-
1960 
19. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, 
Joshua-Tor L, Hannon GJ. Argonaute2 is the catalytic engine of mammalian rnai. 
Science. 2004;305:1437-1441 
 
 110 
20. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell 
Dev Biol. 2011;27:563-584 
21. Senger DR, Davis GE. Angiogenesis. Cold Spring Harb Perspect Biol. 2011;3:a005090 
22. Blanco R, Gerhardt H. Vegf and notch in tip and stalk cell selection. Cold Spring Harb 
Perspect Med. 2013;3:a006569 
23. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality 
in embryos lacking a single vegf allele. Nature. 1996;380:435-439 
24. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan 
KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the 
vegf gene. Nature. 1996;380:439-442 
25. Deng CX, Wynshaw-Boris A, Shen MM, Daugherty C, Ornitz DM, Leder P. Murine fgfr-1 
is required for early postimplantation growth and axial organization. Genes Dev. 
1994;8:3045-3057 
26. Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C. Mice deficient 
for pdgf b show renal, cardiovascular, and hematological abnormalities. Genes Dev. 
1994;8:1875-1887 
27. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby 
R, Olson EN. The endothelial-specific microrna mir-126 governs vascular integrity and 
angiogenesis. Dev Cell. 2008;15:261-271 
28. Meng S, Cao JT, Zhang B, Zhou Q, Shen CX, Wang CQ. Downregulation of microrna-
126 in endothelial progenitor cells from diabetes patients, impairs their functional 
properties, via target gene spred-1. J Mol Cell Cardiol. 2012;53:64-72 
29. Goerke SM, Kiefer LS, Stark GB, Simunovic F, Finkenzeller G. Mir-126 modulates 
angiogenic growth parameters of peripheral blood endothelial progenitor cells. Biol 
Chem. 2015;396:245-252 
 
 111 
30. Lechman ER, Gentner B, Ng SWK, et al. Mir-126 regulates distinct self-renewal 
outcomes in normal and malignant hematopoietic stem cells. Cancer Cell. 2016;29:602-
606 
31. Lechman ER, Gentner B, van Galen P, Giustacchini A, Saini M, Boccalatte FE, 
Hiramatsu H, Restuccia U, Bachi A, Voisin V, Bader GD, Dick JE, Naldini L. Attenuation 
of mir-126 activity expands hsc in vivo without exhaustion. Cell Stem Cell. 2012;11:799-
811 
32. Meister J, Schmidt MHH. Mir-126 and mir-126*: New players in cancer. 
ScientificWorldJournal. 2010;10:2090-2100 
33. Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens 
RT, Heyll K, Noels H, Hristov M, Wang S, Kiessling F, Olson EN, Weber C. Microrna-
126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing dlk1. 
Nat Med. 2014;20:368-376 
34. Cao D, Mikosz AM, Ringsby AJ, Anderson KC, Beatman EL, Koike K, Petrache I. 
Microrna-126-3p inhibits angiogenic function of human lung microvascular endothelial 
cells via lat1 (l-type amino acid transporter 1)-mediated mtor (mammalian target of 
rapamycin) signaling. Arterioscler Thromb Vasc Biol. 2020;40:1195-1206 
35. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, 
Stainier DY, Srivastava D. Mir-126 regulates angiogenic signaling and vascular integrity. 
Dev Cell. 2008;15:272-284 
36. Zhao F, Anderson C, Karnes S, Zhou Q, Ma J, Jin ZG, Bhattacharjee PS, Wang S. 
Expression, regulation and function of mir-126 in the mouse choroid vasculature. Exp 
Eye Res. 2018;170:169-176 
37. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, 
Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microrna profiling reveals 
loss of endothelial mir-126 and other micrornas in type 2 diabetes. Circ Res. 
2010;107:810-817 
 
 112 
38. Potus F, Ruffenach G, Dahou A, et al. Downregulation of microrna-126 contributes to the 
failing right ventricle in pulmonary arterial hypertension. Circulation. 2015;132:932-943 
39. Endo-Takahashi Y, Negishi Y, Nakamura A, Ukai S, Ooaku K, Oda Y, Sugimoto K, 
Moriyasu F, Takagi N, Suzuki R, Maruyama K, Aramaki Y. Systemic delivery of mir-126 
by mirna-loaded bubble liposomes for the treatment of hindlimb ischemia. Sci Rep. 
2014;4:3883 
40. Cross MJ, Claesson-Welsh L. Fgf and vegf function in angiogenesis: Signalling 
pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 
2001;22:201-207 
41. Wakioka T, Sasaki A, Kato R, Shouda T, Matsumoto A, Miyoshi K, Tsuneoka M, Komiya 
S, Baron R, Yoshimura A. Spred is a sprouty-related suppressor of ras signalling. 
Nature. 2001;412:647-651 
42. Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM, Kahn CR, Cantley LC. Increased 
insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc 
Natl Acad Sci U S A. 2002;99:419-424 
43. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. Microrna-126 regulates 
endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A. 
2008;105:1516-1521 
44. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, 
Koppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C. Delivery 
of microrna-126 by apoptotic bodies induces cxcl12-dependent vascular protection. Sci 
Signal. 2009;2:ra81 
45. Berthebaud M, Riviere C, Jarrier P, Foudi A, Zhang Y, Compagno D, Galy A, 
Vainchenker W, Louache F. Rgs16 is a negative regulator of sdf-1-cxcr4 signaling in 
megakaryocytes. Blood. 2005;106:2962-2968 
46. Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med. 
 
 113 
2012;2:a006429 
47. Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, Proebsting S, Wenzel D, Vosen 
S, Franklin BS, Fleischmann BK, Nickenig G, Werner N. Endothelial microparticle-
mediated transfer of microrna-126 promotes vascular endothelial cell repair via spred1 
and is abrogated in glucose-damaged endothelial microparticles. Circulation. 
2013;128:2026-2038 
48. Bai Y, Bai X, Wang Z, Zhang X, Ruan C, Miao J. Microrna-126 inhibits ischemia-induced 
retinal neovascularization via regulating angiogenic growth factors. Exp Mol Pathol. 
2011;91:471-477 
49. Zhou Q, Anderson C, Hanus J, Zhao F, Ma J, Yoshimura A, Wang S. Strand and cell 
type-specific function of microrna-126 in angiogenesis. Mol Ther. 2016;24:1823-1835 
50. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, 
Feiner L, Patel A, Group RS. Long-term outcomes in patients with retinal vein occlusion 
treated with ranibizumab: The retain study. Ophthalmology. 2014;121:209-219 
51. Ye P, Liu J, He F, Xu W, Yao K. Hypoxia-induced deregulation of mir-126 and its 
regulative effect on vegf and mmp-9 expression. Int J Med Sci. 2014;11:17-23 
52. Zhao Y, Srivastava D. A developmental view of microrna function. Trends Biochem Sci. 
2007;32:189-197 
53. Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu T, Bai Y, Shen Y, Yuan W, Jing Q, Qin Y. 
Endothelial-specific intron-derived mir-126 is down-regulated in human breast cancer 
and targets both vegfa and pik3r2. Mol Cell Biochem. 2011;351:157-164 
54. Liu B, Peng XC, Zheng XL, Wang J, Qin YW. Mir-126 restoration down-regulate vegf and 
inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 2009;66:169-
175 
55. Hamada S, Satoh K, Fujibuchi W, Hirota M, Kanno A, Unno J, Masamune A, Kikuta K, 
 
 114 
Kume K, Shimosegawa T. Mir-126 acts as a tumor suppressor in pancreatic cancer cells 
via the regulation of adam9. Mol Cancer Res. 2012;10:3-10 
56. Liu R, Gu J, Jiang P, Zheng Y, Liu X, Jiang X, Huang E, Xiong S, Xu F, Liu G, Ge D, Chu 
Y. Dnmt1-microrna126 epigenetic circuit contributes to esophageal squamous cell 
carcinoma growth via adam9-egfr-akt signaling. Clin Cancer Res. 2015;21:854-863 
57. Schlondorff J, Blobel CP. Metalloprotease-disintegrins: Modular proteins capable of 
promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J 
Cell Sci. 1999;112 ( Pt 21):3603-3617 
58. Fry JL, Toker A. Secreted and membrane-bound isoforms of protease adam9 have 
opposing effects on breast cancer cell migration. Cancer Res. 2010;70:8187-8198 
59. Zigrino P, Steiger J, Fox JW, Loffek S, Schild A, Nischt R, Mauch C. Role of adam-9 
disintegrin-cysteine-rich domains in human keratinocyte migration. J Biol Chem. 
2007;282:30785-30793 
60. Miko E, Margitai Z, Czimmerer Z, Varkonyi I, Dezso B, Lanyi A, Bacso Z, Scholtz B. Mir-
126 inhibits proliferation of small cell lung cancer cells by targeting slc7a5. FEBS Lett. 
2011;585:1191-1196 
61. Yanagida O, Kanai Y, Chairoungdua A, et al. Human l-type amino acid transporter 1 
(lat1): Characterization of function and expression in tumor cell lines. Biochim Biophys 
Acta. 2001;1514:291-302 
62. Wang J, Chen X, Su L, Li P, Cai Q, Liu B, Wu W, Zhu Z. Microrna-126 inhibits cell 
proliferation in gastric cancer by targeting lat-1. Biomed Pharmacother. 2015;72:66-73 
63. Feng R, Chen X, Yu Y, Su L, Yu B, Li J, Cai Q, Yan M, Liu B, Zhu Z. Mir-126 functions as 
a tumour suppressor in human gastric cancer. Cancer Lett. 2010;298:50-63 
64. Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS. Regulation of mirna expression by src 
and contact normalization: Effects on nonanchored cell growth and migration. 
 
 115 
Oncogene. 2009;28:4272-4283 
65. Zhang J, Du YY, Lin YF, Chen YT, Yang L, Wang HJ, Ma D. The cell growth suppressor, 
mir-126, targets irs-1. Biochem Biophys Res Commun. 2008;377:136-140 
66. Zhang Y, Yang P, Sun T, et al. Mir-126 and mir-126* repress recruitment of mesenchymal 
stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 
2013;15:284-294 
67. Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, Chen CZ, Kuo CJ. 
Attribution of vascular phenotypes of the murine egfl7 locus to the microrna mir-126. 
Development. 2008;135:3989-3993 
68. Harris TA, Yamakuchi M, Kondo M, Oettgen P, Lowenstein CJ. Ets-1 and ets-2 regulate 
the expression of microrna-126 in endothelial cells. Arterioscler Thromb Vasc Biol. 
2010;30:1990-1997 
69. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND. Microrna-mediated 
integration of haemodynamics and vegf signalling during angiogenesis. Nature. 
2010;464:1196-1200 
70. Hergenreider E, Heydt S, Treguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, 
Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA, Dimmeler S. 
Atheroprotective communication between endothelial cells and smooth muscle cells 
through mirnas. Nat Cell Biol. 2012;14:249-256 
71. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and 
mechanisms. Circ Res. 2007;100:158-173 
72. Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, Wang Z, 
Rockson SG, van de Rijn M, Botstein D, Brown PO. Endothelial cell diversity revealed by 
global expression profiling. Proc Natl Acad Sci U S A. 2003;100:10623-10628 
73. Weibel ER, Gomez DM. Architecture of the human lung. Use of quantitative methods 
 
 116 
establishes fundamental relations between size and number of lung structures. Science. 
1962;137:577-585 
74. Weibel ER. [morphometric analysis of the number, volume and surface of the alveoli and 
capillaries of the human lung]. Z Zellforsch Mikrosk Anat. 1962;57:648-666 
75. Townsley MI. Structure and composition of pulmonary arteries, capillaries, and veins. 
Compr Physiol. 2012;2:675-709 
76. Aird WC. Phenotypic heterogeneity of the endothelium: Ii. Representative vascular beds. 
Circ Res. 2007;100:174-190 
77. Stevens T. Functional and molecular heterogeneity of pulmonary endothelial cells. Proc 
Am Thorac Soc. 2011;8:453-457 
78. Parker JC, Yoshikawa S. Vascular segmental permeabilities at high peak inflation 
pressure in isolated rat lungs. Am J Physiol Lung Cell Mol Physiol. 2002;283:L1203-
1209 
79. Ofori-Acquah SF, King J, Voelkel N, Schaphorst KL, Stevens T. Heterogeneity of barrier 
function in the lung reflects diversity in endothelial cell junctions. Microvasc Res. 
2008;75:391-402 
80. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler 
Thromb Vasc Biol. 1997;17:1193-1202 
81. King J, Hamil T, Creighton J, Wu S, Bhat P, McDonald F, Stevens T. Structural and 
functional characteristics of lung macro- and microvascular endothelial cell phenotypes. 
Microvasc Res. 2004;67:139-151 
82. Kelly JJ, Moore TM, Babal P, Diwan AH, Stevens T, Thompson WJ. Pulmonary 
microvascular and macrovascular endothelial cells: Differential regulation of ca2+ and 
permeability. Am J Physiol. 1998;274:L810-819 
 
 117 
83. Clark J, Alvarez DF, Alexeyev M, King JA, Huang L, Yoder MC, Stevens T. Regulatory 
role for nucleosome assembly protein-1 in the proliferative and vasculogenic phenotype 
of pulmonary endothelium. Am J Physiol Lung Cell Mol Physiol. 2008;294:L431-439 
84. Alvarez DF, Huang L, King JA, ElZarrad MK, Yoder MC, Stevens T. Lung microvascular 
endothelium is enriched with progenitor cells that exhibit vasculogenic capacity. Am J 
Physiol Lung Cell Mol Physiol. 2008;294:L419-430 
85. Rafii S, Butler JM, Ding BS. Angiocrine functions of organ-specific endothelial cells. 
Nature. 2016;529:316-325 
86. Ding BS, Nolan DJ, Guo P, Babazadeh AO, Cao Z, Rosenwaks Z, Crystal RG, Simons 
M, Sato TN, Worgall S, Shido K, Rabbany SY, Rafii S. Endothelial-derived angiocrine 
signals induce and sustain regenerative lung alveolarization. Cell. 2011;147:539-553 
87. Cao Z, Ye T, Sun Y, et al. Targeting the vascular and perivascular niches as a 
regenerative therapy for lung and liver fibrosis. Sci Transl Med. 2017;9 
88. Goncharova EA, Gladwin MT, Kawut SM. Update in pulmonary vascular diseases 2014. 
Am J Respir Crit Care Med. 2015;192:544-550 
89. Collaborators USBoD, Mokdad AH, Ballestros K, et al. The state of us health, 1990-
2016: Burden of diseases, injuries, and risk factors among us states. JAMA. 
2018;319:1444-1472 
90. Tuder RM, Yoshida T, Arap W, Pasqualini R, Petrache I. State of the art. Cellular and 
molecular mechanisms of alveolar destruction in emphysema: An evolutionary 
perspective. Proc Am Thorac Soc. 2006;3:503-510 
91. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev 
EV, Tuder RM. Ceramide upregulation causes pulmonary cell apoptosis and 
emphysema-like disease in mice. Nat Med. 2005;11:491-498 
92. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, 
 
 118 
Waltenberger J, Voelkel NF. Inhibition of vegf receptors causes lung cell apoptosis and 
emphysema. J Clin Invest. 2000;106:1311-1319 
93. Liu GY, Sabatini DM. Mtor at the nexus of nutrition, growth, ageing and disease. Nat Rev 
Mol Cell Biol. 2020;21:183-203 
94. Helliwell SB, Wagner P, Kunz J, Deuter-Reinhard M, Henriquez R, Hall MN. Tor1 and 
tor2 are structurally and functionally similar but not identical phosphatidylinositol kinase 
homologues in yeast. Mol Biol Cell. 1994;5:105-118 
95. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, 
Yonezawa K. Raptor, a binding partner of target of rapamycin (tor), mediates tor action. 
Cell. 2002;110:177-189 
96. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. Mtor kinase 
structure, mechanism and regulation. Nature. 2013;497:217-223 
97. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. Raft1: A mammalian 
protein that binds to fkbp12 in a rapamycin-dependent fashion and is homologous to 
yeast tors. Cell. 1994;78:35-43 
98. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst 
P, Sabatini DM. Rictor, a novel binding partner of mtor, defines a rapamycin-insensitive 
and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 
2004;14:1296-1302 
99. Condon KJ, Sabatini DM. Nutrient regulation of mtorc1 at a glance. J Cell Sci. 2019;132 
100. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. Mammalian tor 
complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 
2004;6:1122-1128 
101. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, 
Avruch J, Yonezawa K. The mammalian target of rapamycin (mtor) partner, raptor, binds 
 
 119 
the mtor substrates p70 s6 kinase and 4e-bp1 through their tor signaling (tos) motif. J 
Biol Chem. 2003;278:15461-15464 
102. Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP, Kasuga M, 
Nishimoto I, Avruch J. Regulation of eif-4e bp1 phosphorylation by mtor. J Biol Chem. 
1997;272:26457-26463 
103. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, Thomas G. 
Phosphorylation and activation of p70s6k by pdk1. Science. 1998;279:707-710 
104. Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, Dor Y, Zisman P, 
Meyuhas O. Ribosomal protein s6 phosphorylation is a determinant of cell size and 
glucose homeostasis. Genes Dev. 2005;19:2199-2211 
105. Holz MK, Ballif BA, Gygi SP, Blenis J. Mtor and s6k1 mediate assembly of the translation 
preinitiation complex through dynamic protein interchange and ordered phosphorylation 
events. Cell. 2005;123:569-580 
106. Hannan KM, Brandenburger Y, Jenkins A, Sharkey K, Cavanaugh A, Rothblum L, Moss 
T, Poortinga G, McArthur GA, Pearson RB, Hannan RD. Mtor-dependent regulation of 
ribosomal gene transcription requires s6k1 and is mediated by phosphorylation of the 
carboxy-terminal activation domain of the nucleolar transcription factor ubf. Mol Cell Biol. 
2003;23:8862-8877 
107. Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD. Mtorc1 induces purine 
synthesis through control of the mitochondrial tetrahydrofolate cycle. Science. 
2016;351:728-733 
108. Horton JD, Goldstein JL, Brown MS. Srebps: Activators of the complete program of 
cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125-1131 
109. Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE. Rapamycin 
inhibition of the akt/mtor pathway blocks select stages of vegf-a164-driven angiogenesis, 
in part by blocking s6kinase. Arterioscler Thromb Vasc Biol. 2009;29:1172-1178 
 
 120 
110. Sarkar S. Regulation of autophagy by mtor-dependent and mtor-independent pathways: 
Autophagy dysfunction in neurodegenerative diseases and therapeutic application of 
autophagy enhancers. Biochem Soc Trans. 2013;41:1103-1130 
111. Glick D, Barth S, Macleod KF. Autophagy: Cellular and molecular mechanisms. J Pathol. 
2010;221:3-12 
112. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, Iemura S, Natsume T, 
Takehana K, Yamada N, Guan JL, Oshiro N, Mizushima N. Nutrient-dependent mtorc1 
association with the ulk1-atg13-fip200 complex required for autophagy. Mol Biol Cell. 
2009;20:1981-1991 
113. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC. Rapamycin and mtor-independent 
autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related 
proteinopathies. Cell Death Differ. 2009;16:46-56 
114. Goode A, Butler K, Long J, Cavey J, Scott D, Shaw B, Sollenberger J, Gell C, Johansen 
T, Oldham NJ, Searle MS, Layfield R. Defective recognition of lc3b by mutant 
sqstm1/p62 implicates impairment of autophagy as a pathogenic mechanism in als-ftld. 
Autophagy. 2016;12:1094-1104 
115. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin a1 
prevents maturation of autophagic vacuoles by inhibiting fusion between 
autophagosomes and lysosomes in rat hepatoma cell line, h-4-ii-e cells. Cell Struct 
Funct. 1998;23:33-42 
116. Napolitano G, Ballabio A. Tfeb at a glance. J Cell Sci. 2016;129:2475-2481 
117. Dibble CC, Manning BD. Signal integration by mtorc1 coordinates nutrient input with 
biosynthetic output. Nat Cell Biol. 2013;15:555-564 
118. Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, Finan PM, Kwiatkowski DJ, 
Murphy LO, Manning BD. Tbc1d7 is a third subunit of the tsc1-tsc2 complex upstream of 
mtorc1. Mol Cell. 2012;47:535-546 
 
 121 
119. Inoki K, Li Y, Xu T, Guan KL. Rheb gtpase is a direct target of tsc2 gap activity and 
regulates mtor signaling. Genes Dev. 2003;17:1829-1834 
120. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, 
Shaw RJ. Ampk phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 
2008;30:214-226 
121. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, 
Hafen E, Bos JL, Thomas G. Insulin activation of rheb, a mediator of mtor/s6k/4e-bp 
signaling, is inhibited by tsc1 and 2. Mol Cell. 2003;11:1457-1466 
122. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid 
sufficiency and mtor regulate p70 s6 kinase and eif-4e bp1 through a common effector 
mechanism. J Biol Chem. 1998;273:14484-14494 
123. Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. Regulation of torc1 by rag gtpases 
in nutrient response. Nat Cell Biol. 2008;10:935-945 
124. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini 
DM. The rag gtpases bind raptor and mediate amino acid signaling to mtorc1. Science. 
2008;320:1496-1501 
125. Shimobayashi M, Hall MN. Multiple amino acid sensing inputs to mtorc1. Cell Res. 
2016;26:7-20 
126. Broer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol 
Rev. 2008;88:249-286 
127. Poncet N, Taylor PM. The role of amino acid transporters in nutrition. Curr Opin Clin Nutr 
Metab Care. 2013;16:57-65 
128. Yan R, Zhao X, Lei J, Zhou Q. Structure of the human lat1-4f2hc heteromeric amino acid 
transporter complex. Nature. 2019;568:127-130 
 
 122 
129. Verrey F. System l: Heteromeric exchangers of large, neutral amino acids involved in 
directional transport. Pflugers Arch. 2003;445:529-533 
130. Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates 
mtor and autophagy. Cell. 2009;136:521-534 
131. McGivan JD, Bungard CI. The transport of glutamine into mammalian cells. Front Biosci. 
2007;12:874-882 
132. Saxton RA, Knockenhauer KE, Wolfson RL, Chantranupong L, Pacold ME, Wang T, 
Schwartz TU, Sabatini DM. Structural basis for leucine sensing by the sestrin2-mtorc1 
pathway. Science. 2016;351:53-58 
133. Wolfson RL, Chantranupong L, Saxton RA, Shen K, Scaria SM, Cantor JR, Sabatini DM. 
Sestrin2 is a leucine sensor for the mtorc1 pathway. Science. 2016;351:43-48 
134. Elorza A, Soro-Arnaiz I, Melendez-Rodriguez F, et al. Hif2alpha acts as an mtorc1 
activator through the amino acid carrier slc7a5. Mol Cell. 2012;48:681-691 
135. Liu XM, Reyna SV, Ensenat D, Peyton KJ, Wang H, Schafer AI, Durante W. Platelet-
derived growth factor stimulates lat1 gene expression in vascular smooth muscle: Role 
in cell growth. FASEB J. 2004;18:768-770 
136. Barthelemy C, Andre B. Ubiquitylation and endocytosis of the human lat1/slc7a5 amino 
acid transporter. Sci Rep. 2019;9:16760 
137. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. Mtor regulation of autophagy. FEBS Lett. 
2010;584:1287-1295 
138. Arnaoutova I, Kleinman HK. In vitro angiogenesis: Endothelial cell tube formation on 
gelled basement membrane extract. Nat Protoc. 2010;5:628-635 
139. Koike K, Berdyshev EV, Mikosz AM, Bronova IA, Bronoff AS, Jung JP, Beatman EL, Ni 
K, Cao D, Scruggs AK, Serban KA, Petrache I. Role of glucosylceramide in lung 
 
 123 
endothelial cell fate and emphysema. Am J Respir Crit Care Med. 2019 
140. Jiang H, Lei R, Ding SW, Zhu S. Skewer: A fast and accurate adapter trimmer for next-
generation sequencing paired-end reads. BMC Bioinformatics. 2014;15:182 
141. Andrews S. Fastqc. A quality control tool for high throughput sequence data. 2010 
142. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, 
Gingeras TR. Star: Ultrafast universal rna-seq aligner. Bioinformatics. 2013;29:15-21 
143. Paul Flicek MRA, Daniel Barrell, Kathryn Beal, Konstantinos Billis, Simon Brent, Denise 
Carvalho-Silva, Peter Clapham, Guy Coates, Stephen Fitzgerald, Laurent Gil, Carlos 
García Girón, Leo Gordon, Thibaut Hourlier, Sarah Hunt, Nathan Johnson, Thomas 
Juettemann, Andreas K. Kähäri, Stephen Keenan, Eugene Kulesha, Fergal J. Martin, 
Thomas Maurel, William M. McLaren, Daniel N. Murphy, Rishi Nag, Bert Overduin, 
Miguel Pignatelli, Bethan Pritchard, Emily Pritchard, Harpreet S. Riat, Magali Ruffier, 
Daniel Sheppard, Kieron Taylor, Anja Thormann, Stephen J. Trevanion, Alessandro 
Vullo, Steven P. Wilder, Mark Wilson, Amonida Zadissa, Bronwen L. Aken, Ewan Birney, 
Fiona Cunningham, Jennifer Harrow, Javier Herrero, Tim J.P. Hubbard, Rhoda Kinsella, 
Matthieu Muffato, Anne Parker, Giulietta Spudich, Andy Yates, Daniel R. Zerbino, 
Stephen M.J. Searle. Ensembl 2014. Nucleic Acids Research. 2014;42 
144. Liao Y, Smyth GK, Shi W. Featurecounts: An efficient general purpose program for 
assigning sequence reads to genomic features. Bioinformatics. 2014;30:923-930 
145. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for 
rna-seq data with deseq2. Genome Biol. 2014;15:550 
146. Bates DM, Martin; Bolker, Ben; Walker, Steve. Fitting linear mixed-effects models using 
lme4. Journal of Statistical Software. 2015;67 
147. Kuznetsova AB, Per B; Christensen, Rune H. B. Lmertest package: Tests in linear mixed 
effects models. Journal of Statistical Software. 2017;82 
 
 124 
148. Benjamini YH, Yosef. Controlling the false discovery rate - a practical and powerful 
approach to multiple testing. J. Royal Statist. Soc., Series B. 1995;57 
149. Schweitzer KS, Johnstone BH, Garrison J, et al. Adipose stem cell treatment in mice 
attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care 
Med. 2011;183:215-225 
150. Nolan DJ, Ginsberg M, Israely E, et al. Molecular signatures of tissue-specific 
microvascular endothelial cell heterogeneity in organ maintenance and regeneration. 
Dev Cell. 2013;26:204-219 
151. Ebrahimi F, Gopalan V, Smith RA, Lam AK. Mir-126 in human cancers: Clinical roles and 
current perspectives. Exp Mol Pathol. 2014;96:98-107 
152. Lammers S, Scott D, Hunter K, Tan W, Shandas R, Stenmark KR. Mechanics and 
function of the pulmonary vasculature: Implications for pulmonary vascular disease and 
right ventricular function. Compr Physiol. 2012;2:295-319 
153. Scholzen T, Gerdes J. The ki-67 protein: From the known and the unknown. J Cell 
Physiol. 2000;182:311-322 
154. Chavakis E, Dimmeler S. Regulation of endothelial cell survival and apoptosis during 
angiogenesis. Arterioscler Thromb Vasc Biol. 2002;22:887-893 
155. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the 
pathogenesis of copd and pulmonary emphysema. Respir Res. 2006;7:53 
156. Voelkel NF, Douglas IS, Nicolls M. Angiogenesis in chronic lung disease. Chest. 
2007;131:874-879 
157. Tiruppathi C, Malik AB, Del Vecchio PJ, Keese CR, Giaever I. Electrical method for 
detection of endothelial cell shape change in real time: Assessment of endothelial barrier 
function. Proc Natl Acad Sci U S A. 1992;89:7919-7923 
 
 125 
158. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, Park YB. 
Characterization of two types of endothelial progenitor cells and their different 
contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004;24:288-293 
159. Basile DP, Yoder MC. Circulating and tissue resident endothelial progenitor cells. J Cell 
Physiol. 2014;229:10-16 
160. Sasahira T, Kurihara M, Bhawal UK, Ueda N, Shimomoto T, Yamamoto K, Kirita T, 
Kuniyasu H. Downregulation of mir-126 induces angiogenesis and lymphangiogenesis 
by activation of vegf-a in oral cancer. Br J Cancer. 2012;107:700-706 
161. Lum H, Malik AB. Regulation of vascular endothelial barrier function. Am J Physiol. 
1994;267:L223-241 
162. Serban KA, Rezania S, Petrusca DN, et al. Structural and functional characterization of 
endothelial microparticles released by cigarette smoke. Sci Rep. 2016;6:31596 
163. Yoshida T, Mett I, Bhunia AK, et al. Rtp801, a suppressor of mtor signaling, is an 
essential mediator of cigarette smoke-induced pulmonary injury and emphysema. Nat 
Med. 2010;16:767-773 
164. Petrusca DN, Van Demark M, Gu Y, Justice MJ, Rogozea A, Hubbard WC, Petrache I. 
Smoking exposure induces human lung endothelial cell adaptation to apoptotic stress. 
Am J Respir Cell Mol Biol. 2014;50:513-525 
165. Liu W, Wang X. Prediction of functional microrna targets by integrative modeling of 
microrna binding and target expression data. Genome Biol. 2019;20:18 
166. Li H, Chen S, Liu J, Guo X, Xiang X, Dong T, Ran P, Li Q, Zhu B, Zhang X, Wang D, 
Xiao C, Zheng S. Long non-coding rna pvt1-5 promotes cell proliferation by regulating 
mir-126/slc7a5 axis in lung cancer. Biochem Biophys Res Commun. 2018;495:2350-
2355 
167. Adams JM, Cory S. The bcl-2 protein family: Arbiters of cell survival. Science. 
 
 126 
1998;281:1322-1326 
168. Shiojima I, Walsh K. Role of akt signaling in vascular homeostasis and angiogenesis. 
Circ Res. 2002;90:1243-1250 
169. Weigand JE, Boeckel JN, Gellert P, Dimmeler S. Hypoxia-induced alternative splicing in 
endothelial cells. PLoS One. 2012;7:e42697 
170. Liu W, Chen H, Wong N, Haynes W, Baker CM, Wang X. Pseudohypoxia induced by 
mir-126 deactivation promotes migration and therapeutic resistance in renal cell 
carcinoma. Cancer Lett. 2017;394:65-75 
171. Cormerais Y, Giuliano S, LeFloch R, Front B, Durivault J, Tambutte E, Massard PA, de la 
Ballina LR, Endou H, Wempe MF, Palacin M, Parks SK, Pouyssegur J. Genetic 
disruption of the multifunctional cd98/lat1 complex demonstrates the key role of essential 
amino acid transport in the control of mtorc1 and tumor growth. Cancer Res. 
2016;76:4481-4492 
172. Crespo JL, Hall MN. Elucidating tor signaling and rapamycin action: Lessons from 
saccharomyces cerevisiae. Microbiol Mol Biol Rev. 2002;66:579-591, table of contents 
173. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. 
Regulation of pten transcription by p53. Mol Cell. 2001;8:317-325 
174. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of 
the tnf superfamily. Biochem Pharmacol. 2003;66:1403-1408 
175. English WR, Siviter RJ, Hansen M, Murphy G. Adam9 is present at endothelial cell - cell 
junctions and regulates monocyte - endothelial transmigration. Biochem Biophys Res 
Commun. 2017;493:1057-1062 
176. Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro PA, Blobel CP. Adam9 is 
involved in pathological retinal neovascularization. Mol Cell Biol. 2009;29:2694-2703 
 
 127 
177. Castedo M, Roumier T, Blanco J, et al. Sequential involvement of cdk1, mtor and p53 in 
apoptosis induced by the hiv-1 envelope. EMBO J. 2002;21:4070-4080 
178. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mtor): Pro- and anti-
apoptotic. Cell Death Differ. 2002;9:99-100 
179. Tuder RM. Bringing light to chronic obstructive pulmonary disease pathogenesis and 
resilience. Ann Am Thorac Soc. 2018;15:S227-S233 
180. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary 
emphysema. Am J Respir Crit Care Med. 2006;174:886-893 
181. Selman C, Tullet JM, Wieser D, et al. Ribosomal protein s6 kinase 1 signaling regulates 
mammalian life span. Science. 2009;326:140-144 
182. Weichhart T. Mtor as regulator of lifespan, aging, and cellular senescence: A mini-review. 
Gerontology. 2018;64:127-134 
183. Houssaini A, Breau M, Kebe K, et al. Mtor pathway activation drives lung cell 
senescence and emphysema. JCI Insight. 2018;3 
184. Wang XW, Hu LF, Hao J, Liao LQ, Chiu YT, Shi M, Wang Y. A microrna-inducible crispr-
cas9 platform serves as a microrna sensor and cell-type-specific genome regulation tool. 
Nat Cell Biol. 2019;21:522-530 
 
